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1.INTRODUCTION 
 
1.1. Oral drug delivery system:      (Banker G.S and Rhodes C.T., 2009; Chein Y.W., 
2002) 
 An ideal drug delivery system should aid in the optimization of drug therapy 
by delivering an appropriate amount to the intended site and at a desired rate. Hence, 
the DDS should deliver the drug at a rate dictated by the needs of the body over the 
period of treatment. An oral drug delivery system providing a uniform drug delivery 
can only partly satisfy therapeutic and biopharmaceutical needs, as it doesn‟t take in 
to account the site specific absorption rates within the gastrointestinal tract (GIT). 
Therefore there is a need of developing drug delivery system that release the drug at 
the right time, at the specific site and with the desired rate. 
1.2. Drawbacks associated with conventional dosage forms:  (Brahmankar D.M. 
and Jaiswal S.B., 2009; http://www.pharmainfo.net) 
       1. A drug with short biological half life which needs a close succession 
administration is required, so it may increase the missing of dosage form leads to Poor 
patient compliance.  
       2. The uncontrollable fluctuation of drug level may leads to either below 
effective range or over the effective range. 
       3. Plasma concentration verses time profile of dosage form and it‟s difficult to 
achieve the steady state active drug level.  
        4. The rise and fall of drug levels it may give to accumulation of adverse 
effects especially for a drug having less therapeutic index.  
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Figure 1.1: Plasma drug concentration profiles for conventional tablet    
 formulation, a sustained release formulation and a zero order   
 controlled release formulation. 
1.3. Sustained release drug delivery system:  (Banker G.S. and Rhodes C.T., 2009; 
Shargel L. and Andrew B.C.Y., 2005; Aulton M.E., 2007; Ansel H.C., 2009; 
Brahmankar D.M. and Jaiswal S.B., 2009)  
 The main destination of any drug delivery system is to furnish a contributing 
to quantity of a drug to a suitable region in the body and that the required drug 
concentration can be attained promptly and then being maintained. The drug delivery 
system should distribute a drug at a rate dictated by the require of the body for 
particular length of time. Regarding this existing points there are two important 
aspects to delivery system, said as, spatial placement and temporal delivery. Spatial 
placement connected to targeting a drug to particular organ, tissues, cells, or even sub 
cellular area; whereas temporal delivery system deals to controlling the rate of dosage 
form to the targeting region. 
            Sustained release tablets and capsules are mostly taken only once or twice 
daily, compared with immediate release tablet form that may have to take 3 or 4 times 
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a day to attain the same required drug to produce the effect. Typically,  the sustained 
release dosage form to furnish at once release the active component that give the what 
we are desired for cure of disease, followed by remaining quantity of drug should be  
release and maintained the therapeutic effect  over a predetermined length time or 
prolonged period. The sustaining of drug plasma levels furnish by sustained release 
dose often times to eliminate the require for night dose administration, which suitable 
not only the patient but the care given as well. 
            The bulk of research can be focusing toward oral dosages that improve the 
temporal aspect of drug delivery. This approach is a continuously developing in the 
pharmaceutical industry for sustained release oral drug delivery system.  
 The sustained release system for oral use of administration are mostly solid 
and based on dissolution, diffusion or a combination of both, erosion mechanisms, in 
the power to directing the drug release. A delivery system containing hydrophilic and 
hydrophobic polymers and waxes are mixed with active component to furnish drug 
action for a prolonged length of time.  
 The concept of modified release dosage products was previously used to 
describe various types of oral extended release dosage forms, including sustained 
release, sustained action, prolonged action, slow release, long action and retarded 
release.  
 The USP/NF associated with several types of modified-release dosage forms, 
1. Extended release dosage forms. (e.g. sustained release dosage forms, controlled 
release dosage forms) 
2. Delayed release dosage forms (e.g. enteric coated tablets) 
3. Targeted release dosage forms.  
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The United States Pharmacopoeia has been in the term extended release 
and the British Pharmacopoeia has been the term slow release. United States Food 
and Drug Administration has been in the term prolonged release. However the 
review of literature indicates that widely used in terms today are sustained release and 
controlled release. 
Modified release dosage forms: It is a dosage form are defined by the USP as those 
whose drug release characteristics of time course or location are chosen to accomplish 
therapeutic or convenience objective not offered by conventional or immediate release 
form. Also this dosage form which is sufficiently controlled to provide periods of 
prolonged therapeutic action following each administration of a single dose.  
Extended release dosage form: It is a dosage forms release drug slowly, so that 
plasma concentration is maintained at a therapeutic level for a period of time. 
Delayed release dosage form: It is a dosage form which indicates that the drug is not 
being released immediately following administration but at a later time, e.g. enteric 
coated tablets. 
Prolonged release dosage form: It is a dosage form which indicates that the drug is 
provided for absorption over a longer period of time than from a conventional dosage 
form. 
Sustained release dosage form: It is a dosage form which indicates an initial release 
of drug sufficient to provide a therapeutic amount dose soon after administration, and 
then a gradual release over an extended period of time. 
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1.3.1. Advantages of sustained release drug delivery system:
 
(Banker G.S and 
Rhodes C.T., 2009; Chein Y.W., 2002) 
       Some advantages are as follows 
1. Reduction in dosing frequency. 
2. Reduced fluctuation in circulating drug levels. 
3. Increased patient convenience and compliance. 
4. Avoidance of night time dosing. 
5. More uniform effect. 
6. Maximum utilization of drug. 
7. Reduction in GI irritation and other side effects. 
8. Reduction in health care cost through improved therapy. 
9. Improve bioavailability of some drugs. 
1.3.2. Disadvantages of sustained release drug delivery system: (Banker G.S. and 
Rhodes C.T., 2009; Chein Y.W., 2002) 
1. Decreased systemic availability in comparison to immediate release 
conventional dosage form. This may be due to  
 Incomplete release   
 Increased first-pass metabolism, increased instability 
 Site specific absorption, pH dependant solubility, etc. 
2. Poor in vitro-in vivo correlation. 
3. Possibility of dose dumping. 
4. Retrival of drug is difficult in case of toxicity, poisoning, or hypersensitivity 
reactions. 
5. Higher cost of formulation. 
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1.3.3. Rationale of sustained release drug delivery system: 
(http://www.pharmainfo.net; Chein Y.W., 2002)  
 The basic rationale for sustained drug delivery is to alter the pharmacokinetic 
and pharmacodynamics of pharmacologically active moieties by using novel drug 
delivery systems or by modifying the molecular structure and/or physiological 
parameters inherent in a selected route of administration. It is desirable that the 
duration of drug action become more to design properly. Rate controlled dosage form, 
and less, or not at all, a property of the drug molecules inherent kinetic properties.  
As mentioned earlier, primary objectives of controlled drug delivery are to 
ensure safety and to improve efficiency of drugs as well as patient compliance. This 
achieved by better control of plasma drug levels and frequent dosing. For 
conventional dosage forms, only the dose and dosing interval can vary and, for each 
drug, there exists a therapeutic window of plasma concentration, below which 
therapeutic effect is insufficient, and above which toxic side effects are elicited. This 
is often defined as the ratio of median lethal dose (LD 50) to median effective dose 
(ED50).  
1.3.4. Design of sustained release drug delivery system:  (Jithan A., 2007; Ansel 
H.C., 2009; Shargel L. and Andrew B.C.Y., 2005) 
  Practically there are two modern methods are mostly used by pharmaceutical 
manufacturing scientist in the designing of dosage form for sustained release tablet. In 
that the first approach method are mainly involved to modifying of properties like 
physical and chemical nature of the drug and the second method is how to modify the 
release of drug from the prepared dosage form. Physical and chemical characteristic 
of the active component can be developed by formatting complex type, drug and 
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adsorbate formulation, or prodrug synthesis. The conversion of inactive form to active 
nature process is mostly attempted and investigated. The second method is used in the 
formulation development of sustained release system. This is popular method because 
it‟s inherent advantage. The advantage of this method in the design of dosage form is 
independent. The final formulation form could be in a liquid suspension form, a 
capsule or a tablet. 
 Generally some important criteria could be considering in the formulation of a 
sustained release dosage form. Not all the drug ideal characteristic. Drugs which 
shown neither very slow or nor very fast rate of absorption and excretion. Drugs with 
very short half life that is less than 2 hours are poor candidates for sustained release 
because large quantities of drug required for such a formulation.  
 The drug should be absorbed in the gastro intestinal region. Drug 
manufacturing in sustained release tablet it have been good solubility in the intestinal 
and gastric fluid. They are administered in relatively small doses, drug with large 
single doses frequently are not suitable for sustained release. Sustained release dosage 
form mainly used in case of chronic condition than the acute condition. If the 
medicine need for acute condition at that we have to change the dose adjustment by 
physician alike that is given in sustained release form. Drug should have solubility 
and permeability properties. Drug with less protein binding properties. Drug should 
not produce local irritation.  
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1.4. Drug properties relevant to sustained release formulation:    (Chein Y.W., 
2002; http://www.pharmainfo.net) 
The formulation of sustained release drug delivery systems, consider the some 
criteria such as the route of administration, type of  drug delivery system, what 
disease to be treated, the patient, the duration  of treatment  and the characteristic  of 
the drug those above mentioned factor should be considered. The pharmaceutical 
interest to research scientist for designing of the delivery system the following 
properties could be considered in the development of dosage form. These properties 
can be classified as follows. 
  A) Physicochemical properties 
B) Biological properties 
These properties having the greater importance in the design of the drug in the 
delivery system and in the body. But there is no distinction between these two 
categories because the biological properties of a drug as like a function of its 
physicochemical properties. By definition, physicochemical properties of drug that can 
be determined from in vitro study and biological properties will be those that result 
from Pharmacokinetic studies such as absorption, distribution, metabolism and 
excretion of a drug and those resulting from pharmacological experimental study. 
A. Physicochemical factors influencing oral sustained-release dosage form 
design:  
a) Dose size: 
For orally administered systems, there is an upper limit to the bulk size of the 
dose to be administered. In general, a single dose of 0.5- 1.0g is considered maximal 
for a conventional dosage form. This also holds for sustained release dosage form. 
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Compounds that require large dosing size can sometimes be given in multiple 
amounts or formulated into liquid systems. Another consideration is the margin of 
safety involved in administration of large amount of a drug with a narrow therapeutic 
range. 
b) Ionization, pka and aqueous solubility: 
Most drugs are weak acids or bases. Since the unchanged form of a drug 
preferentially permeates across lipid membranes, it is important to note the 
relationship between the pka of the compound and the absorptive environment. 
Presenting the drug in an unchanged form is advantageous for drug permeation. 
Unfortunately, the situation is made more complex by the fact that the drug‟s aqueous 
solubility will generally be decreased by conversion to unchanged form. Delivery 
systems that are dependent on diffusion or dissolution will likewise be dependent on 
the solubility of the drug in aqueous media. These dosage forms must function in an 
environment of changing pH, the stomach being acidic and the small intestine more 
neutral, the effect of pH on the release process must be defined. Compounds with very 
low solubility (<0.01mg/ml) are inherently sustained, since their release over the time 
course of a dosage form in the GI tract will be limited by dissolution of the drug. So it 
is obvious that the solubility of the compound will be poor choices for slightly soluble 
drugs, since the driving force for diffusion, which is the drug‟s concentration in 
solution, will be low. 
c) Partition Coefficient: 
When a drug is administered to the GI tract, it must cross a variety of 
biological membranes to produce a therapeutic effect in another area of the body. It is 
common to consider that these membranes are lipidic; therefore the partition 
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coefficient of oil-soluble drugs becomes important in determining the effectiveness of 
membrane barrier penetration. Compounds which are lipophilic in nature having high 
partition coefficient are poorly aqueous soluble and it retain in the lipophilic tissue for 
the longer time. In case of compounds with very low partition coefficient, it is very 
difficult for them to penetrate the membrane, resulting in poor bioavailability. 
Furthermore, partitioning effects apply equally to diffusion through polymer 
membranes. The choice of diffusion-limiting membranes must largely depend on the 
partitioning characteristics of the drug. 
d) Drug Stability: 
Orally administered drugs can be subject to both acid-base hydrolysis and 
enzymatic degradation. Degradation will proceed at a reduced rate for drugs in solid 
state; therefore, this is the preferred composition of delivery for problem cases. For 
the dosage form that are unstable in stomach, systems that prolong delivery over 
entire course of transit in the GI tract are beneficial; this is also true for systems that 
delay release until the dosage form reaches the small intestine. Compounds that are 
unstable in small intestine may demonstrate decreased bioavailability when 
administered from a sustaining dosage form. This is because more drugs is delivered 
in the small intestine and, hence, is subject to degradation. Propentheline and 
probanthine are representative example of such drug. 
e) Protein binding: 
 Its properties the drugs are binding to blood protein. The drug-Protein 
complex it can act as a depot for drug molecule and to release a drug for prolonged 
period and leads to exhibit a highly binding to plasma. The attractive forces is mainly 
applicable for binding are vanderwaals forces, hydrogen bonding and electrostatic 
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forces. If a drug molecule having hydrophobic in nature its can also increasing the 
binding capacity. Drugs binding to mucin it may increase absorption. e.g. quaternary 
ammonium compounds bound to mucin in the gastro intestinal tract. 
B. Biological factors influencing oral sustained-release dosage form design: 
a) Biological half life: 
The usual goal of an oral SR product is to maintain therapeutic blood levels 
over an extended period of time. To achieve this, drug must enter the circulation at 
approximately the same rate at which it is eliminated. The elimination rate is 
quantitatively described by the half-life (t1/2). Each drug has its own characteristic 
elimination rate, which is the sum of all elimination processes, including metabolism, 
urinary excretion and all over processes that permanently remove drug from the blood 
stream. Therapeutic compounds with short half-life are generally are excellent 
candidate for SR formulation, as this can reduce dosing frequency. In general, drugs 
with halflives shorter than 2 hours such as furosemide or levodopa are poor 
candidates for SR preparation. Compounds with long half-lives, more than 8 hours are 
also generally not used in sustaining form, since their effect is already sustained. 
Digoxin and phenytoin are the examples. 
b) Absorption: 
Since the purpose of forming a SR product is to place control on the delivery 
system, it is necessary that the rate of release is much slower than the rate of 
absorption. If we assume that the transit time of most drugs in the absorptive areas of 
the GI tract is about 8-12 hours, the maximum half-life for absorption should be 
approximately 3-4 hours; otherwise, the device will pass out of the potential 
absorptive regions before drug release is complete. Thus corresponds to a minimum 
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apparent absorption rate constant of 0.17-0.23h
-1
 to give 80-95% over this time 
period. Hence, it assumes that the absorption of the drug should occur at a relatively 
uniform rate over the entire length of small intestine. For many compounds this is not 
true. If a drug is absorbed by active transport or transport is limited to a specific 
region of intestine, SR preparation may be disadvantageous to absorption. One 
method to provide sustaining mechanisms of delivery for compounds try to maintain 
them within the stomach. This allows slow release of the drug, which then travels to 
the absorptive site. These methods have been developed as a consequence of the 
observation that co-administration results in sustaining effect. One such attempt is to 
formulate low density pellet or capsule. Another approach is that of bioadhesive 
materials. 
c) Metabolism: 
Drugs those are significantly metabolized before absorption, either in the 
lumen or the tissue of the intestine, can show decreased bioavailability from slower-
releasing dosage form.  
Hence criteria for the drug to be used for formulating Sustained-Release dosage form 
is,  
 Drug should have low half-life(<5 hrs) 
 Drug should be freely soluble in water 
  Drug should have larger therapeutic window 
 Drug should be absorbed throughout the GIT. 
Even a drug that is poorly water soluble can be formulated in SR dosage form. For the 
same, the solubility of the drug should be increased by the suitable system and later 
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on that is formulated in the SR dosage form. But during this the crystallization of the 
drug, that is taking place as the drug is entering in the systemic circulation, should be 
prevented and one should be cautious for the prevention of the same. 
d) Distribution: 
The distribution of active ingredient into body tissues and extra vascular 
spaces in the body is an important parameter for drug elimination kinetics model. 
Some parameters are using to give idea about distribution of drug. Apparent volume 
of distribution of active component is high it will influence the elimination of dosage 
form and not suitable for making sustained release tablet. The term apparent volume 
of distribution of a drug is mostly used to explain the distribution, including bound to 
the body system. The total apartment volume of distribution for a drug at steady state 
will be calculated by given equation. 
 Vdss = [(K12 + K21) / K21] VP 
Where, 
Vdss =  Apparent volume of distribution at study state level 
K12 =  Drug from central to peripheral compartment 
K21 =  Drug from peripheral to central compartment 
VP =  Volume of central compartment 
e) Side effects: 
 The incidence of side effect of a drug is depends on its therapeutic 
concentration level in blood. It can be remedy by the drug concentration level is 
controlled at which timing that drug exists in blood after administration. Toxic effect 
of a drug is expected above the maximum effective range level and fall in the 
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therapeutic effect if a drug below the level of minimum effective range. So the above 
problem we can solve by making sustained release preparation. 
f) Margin of safety: 
 Therapeutic index of a drug is very important for either sustained or controlled 
release delivery system. Its value only desired the margin of safety. Therapeutic index 
value it has been longer means excellent for preparation of sustained release tablet. 
Narrow therapeutic index of some drug precise to release the active content in 
therapeutic safe and effective range. Some drug like cardiac glycosides that 
therapeutic index value is very small, so it‟s not used for sustained release delivery 
system.   
              Therapeutic index = TD50  ∕ ED50 
                    Where, 
                             TD50   - Median toxic dose 
                             ED50    - Median effective dose 
1.5. Design and fabrication of oral systems:            (Brahmankar D.M. and Jaiswal 
S.B., 2009; Robinson J.R. and Lee V.H.L., 2009; Chein Y W., 2002) 
  The majority of oral controlled release systems rely on dissolution, diffusion or 
a combination of both mechanisms, to generate slow release of drugs into the 
gastrointestinal milieu. The following techniques are employed in the design and 
fabrication of oral sustained release dosage forms.  
       1. Dissolution controlled release  
 Encapsulation dissolution control 
 Matrix dissolution control  
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       2. Diffusion controlled release  
 Reservoir devices 
 Matrix  devices 
3.  Diffusion and dissolution controlled systems 
4.  Ion-exchange resins  
5.  pH - independent formulations 
6. Osmotically controlled release 
7. Altered density formulations  
1.5.1. Dissolution controlled Systems: 
 Drug with a slow dissolution rate will demonstrate sustaining properties, since 
the release of the drug will be limited by rate of dissolution. This being the case, SR 
preparations of drugs could be made by decreasing their dissolution rate. This 
includes preparing appropriate salts or derivatives, coating the drug with a slowly 
dissolving material, or incorporating it into a tablet with a slowly dissolving carrier.
 The dissolution process at steady state, is described by Noyes-Whitney 
equation, 
dc/dt = KDA(Cs-C) = D/h A(Cs-C) 
Where,  
dc/dt  = Dissolution rate 
KD = Diffusion co-efficient 
A         = surface area of the dissolving solid 
Cs = Saturation solubility of the solid 
C = Concentration of solute in bulk solution 
H = Thickness of diffusion layer 
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Encapsulation dissolution control  
 These methods generally involve coating individual particles of drug 
with a slow dissolving material. The coated particles can be directly 
compressed into tablets as in space tabs or placed in capsules as in 
spansule products. 
 Since the time required for dissolution of the coat is a function of 
thickness and aqueous solubility, sustained action can be obtained by 
employing a narrow or a wide spectrum of coated particles of varying 
thickness respectively. 
Matrix dissolution control  
 Those methods involve compressing the drug with a slowly dissolving 
carrier into a tablet form. Here the rate of drug availability is controlled 
by the rate of penetration of dissolution fluid into the matrix. 
 This in turn can be controlled by porosity of the tablet matrix, the 
presence of hydrophobic additives and   wettability of granule surface. 
 
Figure 1.2: Dissolution controlled matrix system 
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1.5.2. Diffusion controlled systems:                                                                                                 
 Basically diffusion process shows the movement of drug molecules from a 
region of higher concentration to one of lower concentration. Diffusion systems are 
characterized by the release rate being dependent on its diffusion through an inert 
membrane barrier. Usually this barrier is an insoluble polymer. 
Membrane reservoir diffusion controlled 
The core of the drug is encapsulated within a water insoluble polymeric 
material. The drug will partition in to the membrane and diffuse in to the fluid 
surrounding the particle or tablet. Cellulose derivatives are commonly used in the 
reservoir types. 
Ficks first law of diffusion describes the diffusion process 
J= -D dc/dx 
Where, 
 D = diffusion coefficient in area/time 
 dc/ dx = change of concentration „c‟ with distance „x‟  
 
Figure 1.3: Schematic representation of reservoir diffusion controlled drug release 
            reservoir 
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Advantages: 
        Zero order delivery is possible; release rate varies with polymer type. 
Disadvantages: 
1. Systems must be physically removed from implant sites. 
2. Difficult to deliver high molecular weight compounds. 
3. Increased cost per dosage unit, potential toxicity if system fails. 
Matrix diffusion controlled: 
It this system a solid drug is dispersed in an insoluble matrix. The rate of drug 
release is controlled by the rate of   diffusion   of drug and not by the rate of solid 
dissolution.  In this model, drug in the outside layer exposed to bath solution is 
dissolved first and then diffuses out of the matrix. The following equation describe the 
rate of release of drug dispersed in an inert matrix system have been derived by 
Higuchi, 
dQ/dt =(DACS/2t)
1/2 
where  
„A‟ is the total amount of the drug in the device,  
„D‟ is the diffusion coefficient of the drug in the polymer, „Cs‟ is the solubility of the 
drug in the polymer,„t‟ is time. 
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Figure 1.4: Release of drug dispersed in an inert matrix system 
Advantages: 
            Easier to produce than reservoir or encapsulated devices, can deliver high 
molecular weight compounds. 
Disadvantages: 
Cannot provide zero order release, removal of remaining matrix is necessary 
for implanted system. 
1.5.3. Dissolution and diffusion - controlled release system: 
         Normally, therapeutic systems will never be dependent on dissolution only or 
diffusion only. In practice, the dominant mechanism for release will over shadow 
other processes enough to allow classification as either dissolution rate limited or 
diffusion controlled.  
Partially soluble membrane system 
The drug is encapsulated in a partially soluble polymer (a polymer that has 
domains that dissolve with time). The drug diffuses through the pores in the polymer 
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coat. For example, a cellulose acetate and HPMC mixture is coated on to the drug 
particles. 
                                                     GI fluids 
                                          
 
Figure 1.5: Partially soluble membrane system 
Matrix system: 
Matrix system encapsulate the drug in a membrane coating, where dissolution 
of the drug in the fluid that penetrates in to the core and diffusion of the drug from 
the core across the polymer membrane makes for a diffusion and dissolution 
controlled system.  
The drug is sparingly soluble in this case, so the release rate is slow and has 
significant influence on the diffusion of drug across the membrane. 
Advantages:  
 Easier to produce than reservoir devices.  
 Can deliver high – molecular weight compounds.  
 Removal from implant sites is not necessary. 
Disadvantages:  
 Difficult to control kinetics owning to multiple process of release.  
 Potential toxicity of degraded polymer.  
 
 
 
Drug       
Drug 
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1.5.4. Ion exchange systems: 
 These are salts of cationic or anionic exchange resins or insoluble complexes 
in which drug release results from exchange of bound drug ions that are normally 
present in GI fluids.   
The use of ion exchange resins to prolong the effect of drugs is based on the 
principle that positively or negatively charged therapeutic molecules combined with 
appropriate resins yield insoluble poly salt resonates. 
1.5.5. Osmotically controlled systems:   
This device is fabricated as tablet that contains water soluble osmotically 
active drug, of that was blended with osmotically active diluents by coating the tablet 
with a cellulose triacetate barrier which functions as a semi permeable membrane. A 
laser is used to form a precision orifice in the barrier, through which the drug is 
released due to development of osmotic pressure difference across the membrane, 
when it is kept in water.  
  Advantages: 
 Zero order release rates are obtainable. 
 Preformulation is not required for different drugs. 
 Release of drug is independent of the environment of the system. 
 Disadvantages: 
 System can be much more expensive than conventional counter parts. 
 Quality control is more extensive than most conventional tablets. 
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Figure 1.6:  Osmotically controlled systems 
1.5.6. pH independent formulations: 
       A buffered controlled release formulation is prepared by mixing a basic or acidic 
drug with or more buffering agents, granulating with appropriate pharmaceutical 
excipients and coating with GI fluid permeable film forming polymer. When GI fluid 
permeates through the membrane the buffering agent adjusts the fluid inside to 
suitable constant pH thereby rendering a constant rate of drug release. 
 
  
 
 
 
 
 
 
Figure 1.7:  Drug delivery from environmentally pH sensitive release systems 
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1.5.7. Altered density formulations: 
        Several approaches have been developed to prolong the residence time of drug 
delivery system in the gastrointestinal tract. 
          High-density approach 
          Low-density approach 
1.6. Matrix tablets:                 (Vyas S.P.and Khar R.K., 2002; Aulton M.E., 2007; 
F.A.A. Adam. et. al., 2007; http://www.pharmainfo.net) 
A matrix system consists of active and inactive ingredients, that are 
homogeneously dispersed and mixed in the dosage form. It is by far the most 
commonly used oral controlled release technology and the popularity of the matrix 
systems can be attributed to several factors which will be discussed in the later 
section. The release from matrix type formulations governed by Fick‟s first law of 
diffusion.  
J = dQt/dt = - D dC/dx 
J is flux, or rate of diffusion, while Q is the amount diffused per unit of time t, and D 
is diffusion coefficient. 
1.6.1. Advantages of matrix system: 
Unlike reservoir and osmotic systems, products based on matrix design can be 
manufactured using conventional processes and equipments. Secondly, development 
cost and time associated with the matrix system generally are viewed as variables, and 
no additional capital investment is required. Lastly, a matrix system is capable of 
accommodating both low and high drug loading and active ingredients with a wide 
range of physical and chemical properties. 
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1.6.2. Limitations of the matrix systems:  
As with any technology, matrix systems come with certain limitations. First, 
matrix systems lack flexibility in adjusting to constantly changing dosage levels as 
required by clinical study outcome. When new dosage strength is deemed necessary, 
more often than not a new formulation and thus additional resources are expected. 
Furthermore, for some products that require unique release profiles (dual release or 
delayed plus extended release), more complex matrix-based technologies such as 
layered tablets are required. 
1.6.3. Types of matrix systems: 
The matrix system can be divided into two categories depending on the types 
of retarding agent or polymeric materials. 
 (a) Hydrophobic matrix system: 
This is the only system where the use of polymer is not essential to provide 
controlled drug release, although insoluble polymers have been used. As the term 
suggests, the primary rate-controlling components of hydrophobic matrix are water 
insoluble in nature. These ingredients include waxes, fatty acids, and polymeric 
materials such as ethyl cellulose, methyl cellulose and acrylate copolymer. To 
modulate drug release, it may be necessary to incorporate soluble ingredients such as 
lactose into formulation. The presence of insoluble ingredient in the formulations 
helps to maintain the physical dimension of hydrophobic matrix during drug release. 
As such, diffusion of active ingredient from the system is the release mechanism, and 
the corresponding release characteristic can be described by Higuchi equation known 
as square root of time release kinetic. The square root of time release profile is 
expected with a porous monolithic, where the release from such system is 
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proportional to the drug loading. In addition, hydrophobic matrix systems generally 
are not suitable for insoluble drug because the concentration gradient is too low to 
render adequate drug release. As such, depending on actual ingredient properties or 
formulation design, incomplete drug release within the gastrointestinal transit time is 
a potential risk and need to be delineated during the development. With the growing 
needs for optimization of therapy, matrix systems providing programmable rates of 
delivery become more important. Constant rate delivery always has been one of the 
primary targets of controlled release system especially for drug with narrow 
therapeutic index. 
 (b) Hydrophilic matrix system: 
The primary rate limiting ingredients of hydrophilic matrix are polymers that 
would swell on contact with aqueous solution and form a gel layer on the surface of 
the system. When the release medium (i.e. water) is thermodynamically compatible 
with a polymer, the solvent penetrates into the free spaces between macromolecular 
chains. The polymer may undergo a relaxation process, due to the stress of the 
penetrated solvent, so that the polymer chains become more flexible and the matrix 
swells. This allows the encapsulated drug to diffuse more rapidly out of the matrix. 
On the other hand, it would take more time for drug to diffuse out of the matrix since 
the diffusion path is lengthened by matrix swelling. Moreover, it has been widely 
known that swelling and diffusion are not the only factors that determine the rate of 
drug. For dissolvable polymer matrix, polymer dissolution is another important 
mechanism that can modulate the drug delivery rate. While either swelling or 
dissolution can be the predominant factor for a specific type of polymers, in most 
cases drug release kinetics is a result of a combination of these two mechanisms. The 
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presence of water decreases the glassy-rubbery temperature (for HPMC from 184°C 
to below 37°C), giving rise to transformation of glassy polymer to rubbery phase (gel 
layer). The enhanced motility of the polymeric chain favours the transport of 
dissolved drug. Polymer relaxation phenomena determine the swelling or volume 
increase of the matrix. Depending on the polymer characteristics, the polymer amount 
in the rubbery phase, at the surface of the matrix, could reach the disentanglement 
concentration; the gel layer varies in thickness and the matrix dissolves or erodes. The 
concentration at which polymeric chains can be considered disentangled was 
demonstrated to correspond to an abrupt change in the rheological properties of the 
gel. This showed a relationship between rheological behaviour of HPMC gels and 
their erosion rate, conforming that the polymer-polymer and polymer-water 
interaction are responsible for the gel network structure and its sensitivity to erosion. 
In turn, they affect drug release rate in the case of poorly soluble drugs. Swelling 
controlled release systems are based upon these principles. Due to the viscoelastic 
properties of the polymer which are enhanced by the presence of cross-linked 
network, anomalous penetrant transport can be observed. This behaviour is bound by 
pure Fickian diffusion and case II transport. Therefore, transport can be reduced to 
three driving forces. The penetrant concentration gradient, polymer concentration 
gradient and osmotic force behavior are observed as a result of polymer network. 
Appropriate polymer can counterbalance normal Fickian diffusion by hindering the 
release of embedded drug, leading to an extended period of drug delivery, and 
possibly zero-order release.  
Drug release from swellable matrix tablets can be affected by glassy-rubbery 
transition of polymer (as a result of water penetration into the matrix where 
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interaction among water, polymer and drug or fillers is considered as the primary 
factor for release control) and the various formulation variables, such as polymer 
grade and type, drug to polymer ratios, drug solubility, drug and polymer particle 
sizes, compaction pressure and presence of additives or excipients in the final 
formulation. They concluded that, the release rate and mechanism of atenolol releases 
from hydrophobic and hydrophilic matrices are mainly controlled by the drug to 
polymer ratio. The results also showed that an increase in the concentration of fillers 
resulted in an increase in the release rate of the drug from matrices and hydrophilicity 
or hydrophobicity of the fillers had no significant effect on the release profile. 
Regarding the mechanism of release, the results showed that in most cases the drug 
release was controlled by both diffusion and erosion depending on the polymer type 
and concentration. On the other hand, incorporation of water soluble fillers like 
polyethylene glycol, lactose and surfactant into gel forming matrices can improve 
phenomenon of insufficient drug release, because these excipients can enhance the 
penetration of the solvent or water into the inner part of matrices, resulting in drug 
release from the matrices. 
(c) Lipid matrix system: 
           These materials manufactured by the lipoid waxes and related ingredients. 
Active form of drug from the dosage form release the content such a matrices 
followed by either diffusion or erosion. A drug release properties are mainly depends 
on the absorption medium fluid component than hydrophobic polymers. Either Stearyl 
alcohol or stearic acid mixed with carnauba wax it has been mainly applicable for 
release retarding polymer in sustained release formulation of tablet.  
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(d) Biodegradable matrix system:           
 These types of polymer are biodegraded either by enzymatic or non 
enzymatic process. It contains the polymeric substance which is composed of 
monomeric linking to other functional group and gives unstable linkage in the 
backbone. Consist of the polymers which comprised of monomers linked to one 
another functional groups and have unstable linkage in the backbone. Finally the 
biodegraded material is excreted in the enzymatic process. Examples of naturally 
obtaining type polymers such as protein and polysaccharides; modified 
synthesized process of natural polymers; synthetic polymers like aliphatic poly 
ester and poly anhydride. 
1.6.4. Polymers used in hydrophilic matrices:      (F.A.A. Adam, et. al., 2007) 
Hydrogel polymers were much investigated in literature on basis of drug 
release and release mechanism from hydrophilic matrix tablets as well as pellets. 
HPMC polymers achieve considerable attention due to their unique properties, and 
they can display good compression characteristics, including when directly 
compressed. They are nontoxic and can accommodate high level of drug loading, and 
also having adequate swelling properties that allows rapid formation of an external gel 
layer which retards or plays a major role in controlling drug release. 
Furthermore, HPMC polymers are well known as pH-independent materials, this 
advantage enable them to withstand fluctuations of pH induce by intra and 
intersubject variations of both gastric pH and gastrointestinal transit time. They have 
been used alone or in combination in formulation of matrix tablets, therefore the 
hydrophilic gel forming matrix tablets are extensively used for oral extended release 
dosage forms due to their simplicity, cost effectiveness and reduction of the risk of 
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systemic toxicity which happens as a result of dose dumping.   The release 
of diclofenac sodium from a mixture of HPMC, Carbopol 940, and lactose as water 
soluble fillers. The results showed that the combination of hydrogels retarded the drug 
better than single polymer. The principal advantage of HPMC matrix formulations is 
the drug release rates are generally independent of processing variables such as 
compaction pressure, drug particle size, increasing of initial granulation liquid and 
incorporation of lubricants.  
The relationship between particle size, tensile strength and the viscosity grade 
of HPMC was complicated. At smaller particle size, an increase in the viscosity grade 
of HPMC resulted in a reduction in the tensile strength of its compacts. However, at 
the large particle size, the tensile strength of HPMC compacts decreased with an 
increase in viscosity grade. For HPMC K100M, there was an increase in tensile 
strength. The combination of HPMC and HPC at different ratios was investigated. 
Increasing the HPMC-HPC ratio increased both the particle size of granules and the 
tablet hardness. The drug release of HPMC matrix tablets was slightly influenced by 
type and concentration of diluents, but the viscosity grade of the polymer did not 
affect the release mechanism. 
An  increase in crushing strength of tablets made of Macrogol 6000 and 
HPMC, due to an increase in compression force during tableting stage and the 
dissolution of formulated tablet was significantly affected by increasing HPMC 
concentration. 
Once daily propranolol extended release tablets using HPMC polymer as a 
retarding agent. The mechanism of the drug release from HPMC matrix tablet 
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followed non-Fickian diffusion, while the in vivo absorption and in vitro dissolution 
showed a linear relationship. 
Other polymers used in hydrophilic matrix preparations include poly ethylene oxide, 
hydroxypropyl cellulose and hydroxyl ethyl cellulose. 
Xanthan gum (XG) was widely used as a thickening agent in food industries, 
but recently introduced in pharmaceutical formulations It is a high molecular weight 
extracellular heteropolysaccharide, produced by fermentation with the gram-negative 
bacterium Xanthamonas campestris. XG shows excellent swelling properties and the 
swelling of the XG polymer matrix shows a square root of time dependence whereas 
drug release is almost time independent.  
Carbopol is a derivative of polyacrylic acid. It is a synthetic, high molecular 
weight, crosslinked polymer. It is readily hydrates, absorbs water and swell. In 
addition, its hydrophilic nature and highly crossliked make it a potential candidate and 
has been used in controlled release drug delivery systems. In the case of tablets 
formulated with Carbopol polymer, the drug is entrapped in the glassy rubbery core in 
the dry state. It forms a gelatinous layer upon hydration. However, this gelatinous 
layer is significantly different structurally from the traditional matrix tablets. The 
hydrogel is not entangled chains of polymer, but discrete microgel made up of many 
polymer particles in which the drug is dispersed. The crosslinked network enables the 
entrapment of drug in the hydrogel domains. Since these hydrogels are not water 
soluble they do not dissolve, and erosion in the manner of linear polymer does not 
occur. Rather, when the hydrogel is fully hydrated, osmotic pressure from within 
works to break up the structure, essentially by sloughing off discrete pieces of the 
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hydrogel. This hydrogel remains intact, and the drug continues to diffuse through the 
gel layer at a uniform rate. 
It is well recognized that key formulation variables are matrix dimension and 
shape, polymer level and molecular weight, as well as drug loading and solubility. 
Other factors such as tablet hardness, type of inactive ingredients and processing 
normally play secondary roles. The choice of manufacturing process such as direct 
blending or granulation typically does not affect product performance significantly, 
although exception does exist. In general, processing and scale-up associating with 
hydrophilic matrices are more robust than other controlled release systems. 
1.6.5. Drug release from matrix systems:   (http://www.pharmainfo.net) 
Drug in the outside layer exposed to the bathing solution is dissolved first and 
then diffuses out of the matrix. This process continues with the interface between the 
bathing solution and the solid drug moving toward the interior. It follows that for this 
system to be diffusion controlled, the rate of dissolution of drug particles within the 
matrix must be much faster than the diffusion rate of dissolved drug leaving the 
matrix. Derivation of the mathematical model to describe this system involves the 
following assumptions: 
a) A pseudo-steady state is maintained during drug release,  
b) The diameter of the drug particles is less than the average distance of drug 
diffusion through the matrix, 
c) The bathing solution provides sink conditions at all times. 
The release behavior for the system can be mathematically described by the following 
equation, 
dM /dh = Co.dh – Cs/2……………1 
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Where, 
dM = Change in the amount of drug released per unit area 
dh = Change in the thickness of the zone of matrix that has been depleted of drug 
Co = Total amount of drug in a unit volume of matrix 
Cs = Saturated concentration of the drug within the matrix.  
Additionally, according to diffusion theory,  
dM = (Dm.Cs)/h . dt...............2 
dM = Change in the amount of drug released per unit area 
dh = Change in the thickness of the zone of matrix that has been depleted of drug 
Co = Total amount of drug in a unit volume of matrix 
Cs = Saturated concentration of the drug within the matrix. 
By combining equation 1 and 2 and integrating 
M = [Cs . Dm . (2 Co - Cs . t )]1/2 ……. 3 
When the amount of drug is in excess of the saturation concentration, then 
M = [Cs . Dm . Co . t]
1/2
 . ……………4 
Equation 3 and 4 indicates the amount of drug release to the square-root of time. 
Therefore, if a system is predominantly diffusion controlled, then it is expected that a 
plot of the drug release vs. square root of time will result in a straight line. Drug 
release from a porous monolithic matrix involves the simultaneous penetration of 
surrounding liquid, dissolution of drug and leaching out of the drug through tortuous 
interstitial channels and pores. The volume and length of the openings must be 
accounted for in the drug release from a porous or granular matrix, 
M = [2 D. Ca . p / T. (2 CO – p. Ca ) t]
1/2
 ….. 5 
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Where, p = Porosity of the matrix 
t = Tortuosity 
Ca = solubility of the drug in the release medium 
Ds = Diffusion coefficient in the release medium 
T = Diffusional pathlength 
For pseudo steady state, the equation can be written as, 
M = [2 D . Ca . CO ( p / T ) t]
1/2……….6 
The total porosity of the matrix can be calculated with the following equation, 
p = pa + Ca / ρ + Cex / ρex ..…….…. 7 
Where, 
p = Porosity 
ρ = Drug density 
pa = Porosity due to air pockets in the matrix 
ρex = Density of the water soluble excipients 
Cex = Concentration of water soluble excipients 
For the purpose of data treatment, Equation 7 can be reduced to, 
M = k . t
1/2
 ..………….. 8 
Where k is a constant, so that the amount of drug released versus the square root of 
time will be linear. If the release of drug from matrix is diffusion-controlled. In this 
case, the release of drug from a homogeneous matrix system can be controlled by 
varying the following parameters, 
• Initial concentration of drug in the matrix 
• Porosity 
• Tortuosity 
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• Polymer system forming the matrix 
• Solubility of the drug. 
1.7. Methods used in tablet manufacturing:   (Lieberman H.A. and Lachman L., 
1999; Ansel H.C., 2009) 
                A. Wet granulation 
                B. Dry granulation      
                C. Direct compression 
Granulation: 
                Generally the powders material cannot be punching directly into tablet form, 
because (a) the material should not have bonding a property to each other into 
compaction and (b) insufficient flow character from the hopper into die cavity. For 
this reason and this nature of material we can go for granulation methods. 
The reason for granulation: 
  Become the pharmaceutical ingredient are free flowing 
  Increase the denseness of  ingredient 
  We can formulate uniform granular size that does not existing apart  
  Produce better  compression  characteristic  of  drug 
  Controlling  the  rate of  drug release from the dosage form 
  Reduce  dust in granulation technique 
  The  appearance  of  tablet can be achieved 
A. Wet granulation: 
           Size reduction of active ingredient and inactive ingredient, proper mixing of 
crushed powders, preparation of binder solution by using standard binder, pouring the 
binding agent with powder mixture to form coherent mass, the wet mass is screening 
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using 6 to 12 sieve mesh, drying the shifted granules, sieving prepared granules with 
lubricant and glidant, mixing screened granules with lubricant and glidant, finally 
compressed into tablet form.  
Advantages: 
 Powder material is converted into granular form by adding binding solution, 
the use of binder it‟s coating the each powder material to get a granules which having 
better cohesiveness and compressibility for manufacturing of tablet.  
 If an active component it has been high label claim and also improper flow 
characteristic can be prepared by wet granulation technique to acquire excellent flow 
of granules and its granular material having cohesiveness for punching.  
 Uniform distribution of active ingredient as well as uniform active content 
quantity of prepared dosage form. 
 In many pharmaceutical ingredient can cause the dust and airborne pollute it 
could be handling without producing this problem by granulation method. 
 In these methods prevent the agglomeration of ingredient in a homogeneous 
powder mixture under processing, shifting and handling.  
 Controlled release dosage form can be developed by the manufacturing 
scientist using better binding agent and polymer or solvent. 
 This procedure entrapment of air in the material can be reduced.  
Disadvantages: 
 It needs a number of equipments in the production area. 
 There is a chances of pollute than the direct compression method. 
 In these method timing period is increase because moistening the material and 
drying process. 
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 This method not suitable for sticky ingredient and hygroscopic substance. 
B. Dry granulation: 
            In dry granulation size reduction of active ingredient and inactive ingredient, 
mixing of milled material, directly compressed into tablet, further the prepared tablet 
is milled this process called slugging, sieving of slug material, finally mixing with 
lubricant and glidant and tablet punching. 
Advantages: 
 In this method the material are highly heats sensitive and destroyed in 
moisture condition so we can formulate by dry granulation method. 
 It needs less space for placing the equipment and processing step than other 
methods. 
 The ingredient cost is smaller in extent. 
Disadvantages: 
 For this method, either the active material or inactive material should have 
binding properties and cohesive nature. 
 The ingredient must be in the nature of either crystalline or amorphous form. 
C. Direct compression: 
           Size reduction of active component and inactive component, mixing of milled 
ingredients, tablet compression. 
Advantages: 
 The exposing of active component to moisture and thermal can be prevented. 
 These methods the cost of preparation can be minimized and reduce the labor 
cost. 
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 Tablet manufactured by this process very easy to disintegrating molecule from 
the dosage form.  
 The equipment like granulators and dryers and solvent are not needed in 
manufacturing of tablets by this method. 
Disadvantages: 
 The uniformity of color is difficult to achieve in manufacturing of tablets. 
 In this process cost of materials is a great vertical extent. 
 In this method produce dust and air pollute during manufacturing process.  
 Content uniformity is not maintained, because agglomeration and separation 
of drug molecule it will occur in transferring from hopper into die cavity.      
1.8. ARTHRITIS: (Tripathi K.D., 2003; Rang A.P., et al., 2001; Brunton L., et al., 
2008)
 
“Arthritis” literally means “inflamed joints”. Arthritis primarily affects the 
joints; it also attacks muscles and connective tissues of the surrounding organs. 
Arthritic disease stems from injuries, defects in the immune system, wear and tear on 
the joints, infections or genetic predisposition. 
A. Osteoarthritis: 
A degenerative joint disease and the most common form of arthritis and joint 
disorders, is the gradual deterioration of cartilage, usually in the larger, weight 
bearing joints such as the hips, knees, and spine. This wear and tear is normal 
process predominantly found in people of age 55 and older. Among those younger 
than 45, it occurs more often in men.  The joints are not always inflamed; the 
articular cartilage may begin to flake and crack, due to over use or injury. In severe 
cases the underlying bone becomes thickened and distorted. Scar tissue may then 
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replace damaged cartilage. If movement becomes painful and restricted, lessened use 
of the associated muscles will lead to their atrophy. 
B. Rheumatoid arthritis: 
Rheumatoid arthritis is traditionally considered a chronic, inflammatory 
autoimmune disorder that causes the immune system to attack the joints. It is a 
disabling and painful inflammatory condition, which can lead to substantial loss of 
mobility due to pain and joint destruction. Rheumatoid arthritis is a systemic disease, 
often affecting extra articular tissues throughout the body including the skin, blood 
vessels, heart, lungs and muscles.        
The joint lining, called the synovium, becomes inflamed in cases of 
rheumatoid arthritis, leading to pain, stiffness, warmth, redness and swelling. These 
inflamed cells release an enzyme that may even digest cartilage and bone. 
1.8.1   Biochemical mechanism:
 
The normal synovial lining of diarthodial joints is a delicate tissue layer up to 
three cells thick and a loosely arranged stroma with connective tissue, 
microvasculature and lymphatics. Inflammatory synovitis is the key pathological 
feature in rheumatoid arthritis. Its characteristics are synovial hyperplasia, 
inflammatory cell infiltration and vascularity. Initially edema and fibrin deposition 
predominate. Subsequently, there is synovial lining layer hyperplasia involving 
macrophage and fibroblast like synoviocytes. This hyperplasia is accompanied by 
infiltration of T cells, B cells, macrophages and plasma cells in the sublining layer. 
A number of different pathological mechanisms are involved in rheumatoid 
arthritis. Lymphocytes have an important role and many inflammatory cells in the 
synovial sublining layer are lymphocytes, especially T cells.  
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Figure 1.8: The Pathophysiology of Rheumatoid Arthritis 
 
1.8.2. Symptoms:  
The exacerbation of the disease peaks at only certain times of the day and the 
cardinal symptoms of rheumatoid arthritis include: 
 Stiffness, swelling and pain of one or more joints of the body characteristically 
severe in the morning, fatigue and weakness.  
 Stiffness following periods of immobility, which gradually improves with 
movement.  
 Rheumatoid nodules (lumps of inflamed cells) under the skin usually found on 
the bony part of the fore arm, ankle and fingers.  
 Minor fever, anemia and weight loss. 
1.8.3. Treatment: 
Pharmacological treatment of rheumatoid arthritis can be divided into 
 Disease modifying anti-rheumatic drugs  
 Anti-inflammatory agents and analgesics. 
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 DMARDs have been found to produce durable remissions and delay or 
halt disease progression. In particular they prevent bone and joint damage 
from occurring secondary to the uncontrolled inflammation.  
1.8.4. Disease modifying anti-rheumatic drugs (DMARDs): 
DMARDs can be further subdivided into Xenobiotic agents and biological 
agents. Xenobiotic agents are those DMARDs that do not occur naturally in the 
body, as opposed to biologicals. 
Xenobiotics include, 
 Azathioprine, Cyclosporine, D-penicillamine, gold salts, Leflunomide, Minocycline, 
Hydroxychloroquine, Methotrexate, and Sulfasalazine.  
Biological agents: 
Tumor necrosis factor (tnf α) blockers - Etanercept (Enbrel), Infliximab (Remicade),        
Interleukin-1 blockers     - Anakinra  
Anti-B cell (CD20) antibody    - Rituximab   
1.8.5. Anti-inflammatory agents and analgesics:
  
The treatment of arthritic conditions relies on medicines that fight joint 
swelling, stiffness and pain. Circadian rhythm affects the arthritic medication. 
NSAIDs reduce the swelling, stiffness and pain of arthritis. Taking the medicines at 
the wrong time of day compromises their effectiveness and increases the risk of side 
effects such as indigestion, stomach ulcers, headache, anxiety and dizziness. 
Chronotherapy provides ways of increasing the effectiveness and safety of arthritic 
medications.  
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Anti-inflammatory agents include, 
A. Glucocorticoids:  
Non steroidal anti-inflammatory drugs also act as analgesics. 
B. Non steroidal anti -inflammatory drugs:  
NSAIDs are drugs with analgesic, antipyretic and anti inflammatory effects 
that reduce pain, fever and inflammation. The term "non steroidal" is used to 
distinguish these drugs from steroids, which (among a broad range of other effects) 
have a similar eiconoside depressing, anti inflammatory action.  
Mechanism of action:  
Most NSAIDs act as non selective inhibitors of the enzyme cyclooxygenase, 
inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) 
isoenzymes.  
Cyclooxygenase catalyzes the formation of prostaglandins and thromboxane 
from arachidonic acid (Derived from the cellular phospholipid bilayer by 
phospholipase A2).  
 
 
 
 
 
 
Figure 1.9: Mechanism of action of NSAIDs 
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1.8.6. Classification of NSAIDs: 
    A. Chemical classification: 
Table 1.1: Classification of NSAIDs 
 
 
 
 
 
 
B. Classification based on COX selectivity:  
1. Non COX selective NSAIDS: 
Aspirin, Indomethacin, Diclofenac, Piroxicam, Ibuprofen, Naproxen,    
Mefenamic acid. 
2. Preferential COX-2 inhibitors: 
Nimesulide, Meloxicam, Nabumetone, Aceclofenac 
3. Highly selective COX-2 inhibitors:  
1
st
 generation :  Celecoxib, Rofecoxib 
2
nd
 generation :  Valdecoxib, Parecoxib, Etoricoxib, Lumiracoxib. 
 
S.No. Category Drug 
1. Salicylates Aspirin 
2. Indoles Indomethacin 
3. Pyrazoles Phenyl butazone 
4. Fenamate Mefenamic acid 
5. Propionic acid Ibuprofen, Ketoprofen 
6. Phenyl acetic acid  Diclofenac, Aceclofenac, Flurbiprofen 
7. Oxicam Piroxicam, Tenoxicam, Meloxicam 
8. Sulphonanilide Nimesulide 
9. Coxibs Celecoxib, Rofecoxib,Valdecoxib, Parecoxib 
10 Alkanone Nabumetone 
11 Aryl propionic acid Naproxen 
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2. NEED AND OBJECTIVE 
  
Aceclofenac is a non-steroidal anti-inflammatory, analgesic and antipyretic 
agent. It is a prodrug of Diclofenac, in the inflammatory cells it gets converted into 
diclofenac and 4-hydroxy diclofenac. Aceclofenac has the more COX-2 specificity 
than diclofenac, as it is active only in inflammatory cells it has less GI stress than 
diclofenac. It has short biological half-life (4 hours), and the usual oral dosage 
regimen is 100 mg taken 2 times a day. 
The basic goal of therapy is to achieve a steady state blood or tissue level that 
is therapeutically effective and non-toxic for an extended period of time. Sustained 
release drug delivery systems, with an aim of improved patient compliance, better 
therapeutic efficacy, less side effects and reduced dosage regimen with less toxicity 
for treatment for many acute and chronic diseases. 
Non–Steroidal Anti-Inflammatory Drugs (NSAIDs) are considered to be the 
first line drug in the symptomatic treatment of rheumatoid arthritis, osteoarthritis and 
ankylosing spondylitis. Aceclofenac is one of the emerging NSAIDs molecules for 
arthritis treatment 
 To minimize the frequent dosing  
 To prolong the pharmacological effect and  
 To improve patient compliance, a sustained release formulation of 
Aceclofenac is very much desirable.  
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Among the many techniques used for modulating the drug release profile, the 
most commonly used method is embedment of the drug into a polymer matrix.  
The matrix may be formed by either dissolving or dispersing the drug uniformly 
in the polymer mass. Such polymer matrices can give,  
 Desirable release profiles 
 Cost effective manufacturing method and also  
 Broad regulatory acceptance.  
Hence, in the present work, an attempt is made to develop sustained-release 
matrix tablets of Aceclofenac, with the use of various hydrophilic polymers for their 
sustaining effect. Wet granulation technique is used for tablet formulation along with 
the addition of suitable additives by using of hydrophilic polymers of HPMC K15M, 
Carboxy methyl cellulose and Xanthan gum. 
Objectives of the work: 
To design of sustained release dosage form of Aceclofenac that will help in 
releasing only small quantities of drug over a prolonged period of time.  
 To study the effect of type of polymers and polymer concentration on release 
profiles of sustained release Aceclofenac formulations. 
 To study the different types of schemes on release profiles of sustained release 
Aceclofenac formulations. 
 To arrive at better formulation based on comparison amongst the studied ones. 
 To perform stability studies as per ICH guidelines. 
 
  
     
 
 
 
 
 
 
 
 
      Plan of Work 
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3. PLAN OF WORK 
 
 Literature survey 
 Selection and procurement of suitable drug candidate and excipients 
 Preformulation studies 
 Characterization of drug 
 Melting point determination 
 Solubility determination 
 UV spectra ( max) 
 IR spectra 
 Loss on drying 
 Standard carve of  Aceclofenac 
 Percentage purity of drug 
 Drug polymer interaction study 
 Fourier transform Infra-Red (FTIR) spectroscopy 
 Differential Scanning Calorimetry (DSC) 
 Characterization of Powdered blend 
 Bulk density 
 Tapped density 
 Carr‟s index 
 Hausner‟s ratio 
 Angle of repose 
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 Formulation of  Sustained release matrix tablet of   Aceclofenac 
 Evaluation of  Sustained release matrix tablet  of Aceclofenac  
 Appearance 
  Dimensions ( Thickness and Diameter) 
 Hardness 
 Percent friability 
 Weight variation test 
 Drug content of Aceclofenac  (assay) 
 In-vitro dissolution studies 
 Kinetic of In-vitro Drug Release 
 Stability studies 
 Result and discussion 
 Summary and conclusion   
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Aceclofenac Sustained Release  Tablets                 LITERATURE REVIEW                                                                                             
 
Adhiparasakthi College of Pharmacy, Melmarvathur. Page 47 
4. LITERATURE REVIEW 
 
Sahoo S.K., et al., (2008): In the present study Aceclofenac gelatin 
micropellets were prepared by cross linking technique using glutaraldehyde has a 
cross linking agent. The effect of the drug polymer ratio, temperature of oil phase 
amount of glutarldehyde and stirring micropellets having an entrapment efficacy, 
micropellets size and drug release characteristics spherical micropellets having an 
entrapment efficiency of 57-97% were obtained. 
Keny R.V., et al., (2009): The present study was aimed to develop once daily 
extended release matrix tablets of minocycline hydrochloride, using hydroxyl propyl 
methyl cellulose either alone or in combination with ethyl cellulose as the matrix 
material in different proportions. The formulated tablets were also compared with a 
marketed product. The results of the dissolution study indicate that formulations FC-
IV, FC-V, FC-VI, shows maximum drug release upto 24 hr. Drug release from matrix 
occurred by combination of two mechanisms diffusion of tablet matrix and erosion of 
tablet surface which was reflected from Higuchi‟s model and Erosion plot. 
Nasra M.A., et al., (2007): The potential of matrix, multilayer and 
compression coated tablets of metronidazole to reach the colon intact has been 
investigated in vitro, using pectin as a carrier. Matrix tablets containing various 
proportions of pectin were prepared by wet granulation and direct compression 
techniques. In vitro release studies indicated that matrix and multilayer tablets failed 
to control the drug release in the physiological environment of stomach and small 
intestine, compression coated tablet formulations F13, F14 and F12 released about 
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70.25% ± 9.9%, 51.3% ± 5.45% and 20% ± 5.01% drug respectively at the end of 24 
hours. These tablets exhibited no change either in physical appearance or dissolution 
pattern after storage at ambient temperature (25°C) for 12 months.
 
Manjanna K.M., et al., (2009):
 
The objective of the present study was 
microencapsulate the Aceclofenac (NSAIDs) by ionotropic gelation technique by 
using sodium alginate as hydrophilic carrier in various polymer interactions were 
observed in FT-IR studies. In-vitro drug release profile of Aceclofenac from 
microbeads was examined in simulated gastric fluid pH1.2 for initial 2 h, mixed 
phosphate buffer pH6.8 upto 6 h and simulated intestinal pH 7.2 at end of 24 h 
studies. The release of drug from the microbeads was pH dependent, showed 
negligible drug release in pH1.2. Under neutral conditions the beads will swell and 
the drug release depend on the swelling and erosion process resulting optimum level 
of drug released in a sustained manner and exhibited zero-order kinetics followed by 
super case-II transport. 
Ganesan V., et al., (2008): The objective of the study was to develop guar 
gum matrix tablets for oral controlled release of Ambroxol hydrochloride. According 
to the theoretical release profile calculation, a twice daily sustained release 
formulation should release 19.6 mg of Ambroxol hydrochloride in 1 hour like 
conventional tablets, and 5.2 mg per hour upto 12 hours. Ambroxol hydrochloride 
matrix tablets containing either 30%wt/wt of low viscosity (F-III), 25% wt/wt 
medium viscosity (F-VI) or 20% wt/wt high viscosity (F-IX) guar gum showed 
sustained release. Applying exponential equation, the selected formulations F-III and 
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F-VI showed diffusion-dominated drug release and followed first order kinetics. The 
mechanism of drug release from F-IX was diffusion coupled with erosion.
 
Gothi G.D., et al., (2010): In the present investigation an attempt was made to 
reduce the frequency of dose administration, to prevent nocturnal heart attack and to 
improve the patient compliance by developing extended release (ER) matrix tablet of 
metoprolol succinate. The effect of concentration of hydrophilic (HPMC K100M, 
Xanthan gum) on the release rate of metoprolol succinate was studied. 
Anton S.A., et al., (2009): The objective of the present work was to develop 
sustained release matrix tablets of Ondansetron Hydrochloride (5mg) formulated 
employing Hydroxy propyl Methyl Cellulose (HPMC), polymer and the sustained 
release behavior of the tablets was investigated. Tablets were prepared by wet 
granulation methods.
 
Krishnaiah Y.S.R., et al., (2004): The objective of the present study is to 
carry out pharmacokinetic evaluation of oral controlled release formulation (guar 
gum-based three layer matrix tablets) containing highly soluble metoprolol tartrate as 
a model drug. The plasma concentration of metoprolol tartrate was estimated by 
reverse-phase HPLC. The pharmacokinetic parameters were calculated from the 
plasma concentration of metoprolol tartrate versus time data. The results of the study 
indicated that guar gum three-layer matrix tablets were able to provide oral controlled 
delivery of highly water-soluble drug such as metoprolol tartrate in humans.
 
Mishra B., et al., (2005): The present study aimed to formulate and evaluate 
hydrophilic matrix tablets of diltiazem hydrochloride to achieve a controlled and 
sustained drug release with reduced frequency of drug administration, reduced side 
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effects and improved patient compliance. Matrix tablets of diltiazem hydrochloride 
were prepared using polymers like hyroxypropyl methylcellulose (HPMC K15M, 
HPMC K4M), sodium carboxy methylcellulose (SCMC) and Guar gum, and different 
diluents like lactose, starch, microcrystalline cellulose.
 
Chandria M., et al., (2009): The present investigation attempt has been made 
increase therapeutic efficacy, reduce frequency of administration and improve patient 
Compliance, by developing sustained release matrix tablets of Zidovudine, were 
developed by using drug polymer ratio of kollidon SR, HPMC K15M and HPMC 
K100M as matrix tablet formulation were compressed by direct compression and wet 
granulation method. Compressed tablets were evaluated for uniformity of weight, 
content of active ingredient, friability, hardness, thinkess, in-vitro dissolution, and 
swelling index, all formulation showed compliance with pharmacopoeial standards.
 
Morkhade D.M., et al., (2007): Natural gum, damer was investigated as a 
novel microencapsulating material for sustained drug delivery. Microparticles were 
prepared by oil-in-oil emulsion solvent evaporation method. Ibuprofen and diltiazem 
hydrochloride were used as model drugs. in-vitro drug release kinetics.. The increase 
in gum:drug ratio showed an increase in particle size, encapsulation efficiency and 
decrease in drug release rate in all cases. Drug release profiles of all microparticles 
followed zero order kinetics.  
Saptarshi D., et al., (2010): An attempted was to formulate the oral sustained 
release metformin hydrochloride matrix tablets by using hydroxyl methyl cellulose 
polymer (HPMC) as rate controlling factor and to evaluate drug release parameters as 
per various release kinetic models. It is observed that the basic goal of therapy in the 
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development of metformin hydrochloride release dosage form is to increase 
bioavailability; reduce risk of hospitalization, deliver drug at a near constant rate for 
approximately 12h; independent of food intact and gastrointestinal pH. The dry 
granulation technique was used to compress the tablet as powder showed the poor 
flowability; wet granulation technique was not selected for the present work. 
Sarojini S., et al., (2010): The purpose investigation highlights the 
formulation and optimization of floating tablets of Theophylline as a model drug. 
Formulations were optimized for type of filler and different concentration of 
Polyethylene oxide. 
Tabandeh H., et al., (2003): A sustained release tablet formulation should 
ideally have a proper release profile insensitive to moderate changes in tablet hardness 
that is usually encountered in manufacturing. In the study, matrix Aspirin 
(acetylsalicylic acid) tablets with ethyl cellulose (EC), Eudragit RL100, Eudragit 
S100 were prepared by direct compression. The release behaviors were then studied 
in two counterpart series of tablets with hardness difference of three Kp units, and 
compared by non-linear regression analysis. 
Varshosaz J.,  et al., (2002):
 
The buccoadhesive controlled-release tablets for 
delivery of Nifedipine were prepared by direct compression of carboxymethyl 
cellulose (CMC) with carbomer (CP), which showed superior bioadhesion properties 
compared to polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxypropyl 
methylcellulose (HPMC), and acacia in a modified tensiometry method in vitro. The 
tablets containing 30 mg of Nifedipine and various amounts of CMC and CP showed 
a zero-order drug release kinetic.
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Yeole P.G., et al., (2006): In the present investigation, an attempt has been 
made to increase therapeutic efficacy, reduce frequency of administration, and 
improve patient compliance, by developing sustained release matrix tablets of 
Diclofenac sodium. Sustained release matrix tablets of Diclofenac sodium, were 
developed by using different drug:polymer ratios, such as F1(1:0:12), F2(1:0:16), 
F3(1:0:20), F4(1:0:24) and F5(1:0:28). Xanthan gum was used as matrix former, and 
microcrystalline cellulose as diluents. All the lubricated formulations were 
compressed using 8mm flat faced punches. 
 
Ghosh S., et al., (2009):
 
The objective of the study was to develop matrix 
tablets for oral controlled release of Aceclofenac. Matrix tablets of Aceclofenac, using 
various viscosity of hydrophilic polymer HPMC in two different proportions, 
hydrophobic polymer ethyl cellulose and Guar gum were prepared by wet granulation 
method and subjected to in vitro drug release studies. The drug release from all 
HPMC matrix tablets followed various release kinetics, formulation no - F7 followed 
Higuchi kinetics. Furthermore, the results of the in vitro studies in pH 7.5 phosphate 
buffer medium showed that F7 tablets provided controlled release comparable with 
market sustained release formulation (Aeroff-SR tablets).
 
Radika P.R., et al., (2008): Delayed release microspheres of Aceclofenac 
were formulated using enteric polymer, Cellulose acetate phthalate (CAP) prepared 
by solvent evaporation technique. The effect of various other modern enteric 
polymers such as HPMC, Eudragit L-100, Eudragit S-100 on the release of 
Aceclofenac from the CAP have been evaluated. 
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Soni T., et al., (2008): The development of a meaningful dissolution 
procedure for drug products with limited water solubility has been a challenge to the 
pharmaceutical industry. Aceclofenac (BCS Class II drug) is a non steroidal anti-
inflammatory drug. There is no official dissolution medium available in the literature. 
In the present study, parameters such as solubility, medium pH, surfactant type, 
dissolution behavior of formulations, and influence of sink conditions, stability, and 
discriminatory effect of dissolution testing were studied for the selection of a proper 
dissolution medium. 
Srinivas Mutalik., et al., (2008): The purpose of this study was to develop a 
once daily sustained release tablet of Aceclofenac using chitosan and an enteric 
coating polymer. Overall sustained release for 24 h was achieved by preparing a 
double-layer tablet in which the immediate release layer was formulated for a prompt 
release of the drug and the sustained release layer was designed to achieve a 
prolonged release of drug. Good equivalence in the drug release profile was observed 
when drug release pattern of the tablet containing chitosan and hydroxypropyl 
methylcellulose phthalate (M-7) was compared with that of marketed tablet. 
 
Umesh.D. Shivhare., et al., (2009): The objective of the present study was to 
develop “once daily” sustained release tablets of aceclofenac by wet granulation using 
carboxy -polymethylene polymer. The drug excipient mixtures were subjected to 
preformulation studies while the tablets were subjected to physicochemical studies, in 
vitro drug release, stability studies and validation studies. 
Basak S.C., et al., (2010): Monolithic matrix tablets of Ambroxol 
Hydrochloride were formulated as sustained release tablets employing Hydroxy 
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Propyl Methyl Cellulose polymer, and the sustained release matrix tablets containing 
75mg Ambroxol hydrochloride were developed using different drug polymer ratios of 
Hydroxy Propyl Methyl Cellulose. Tablets were prepared by direct compression.  
Formulation was optimized on the basis of acceptable tablet properties and in vitro 
drug release. 
Yadav I.K. et al., (2010): The objective of the present study was to develop 
the oral sustained release matrix tablets of Aceclofenac using hydrophilic and 
hydrophobic polymers. Aceclofenac is a non steroidal anti-inflammatory agent used 
in symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing 
spondylitis and its biological half life is 4 hrs. Controlled release formulations of 
Aceclofenac (200 mg) were prepared by direct compression method. The drug release 
from optimized formulations F1, F4 and F7 was extended for a period of 12 h. The 
kinetic treatment to optimized formulations showed that the release of drug follows 
zero order model and Super Case II transport for F1 and F7. 
Suvakanta D., et al., (2010): In this paper were reviewed mathematical 
models used to determine the kinetic of drug release from drug delivery system the 
quantitative analysis of the values are obtained in dissolution/ release rate is easier 
when mathematical formula used to describe the process. The mathematical modeling 
can optimize to design therapeutic design of therapeutic device to yield information 
on the various efficacy of various release models. 
Kabir A.K., et al., (2009): Objective of this study was to develop a sustained 
release matrix tablet of Aceclofenac using hydroxypropyl methylcellulose (HPMC 
K15M and HPMC K100M CR) in various proportions as release controlling factor by 
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direct compression method. The results of dissolution studies indicated that the 
formulations F-2 and F-3 could extend the drug release up to 24 hours. From this 
study, a decrease in release kinetics of the drug was observed when the polymer 
concentration was increased. Kinetic modeling of in vitro dissolution profiles revealed 
the drug release mechanism ranges from diffusion controlled or Fickian transport to 
anomalous type or non-Fickian transport, which was only dependent on the type and 
amount of polymer used. The drug release followed both diffusion and erosion 
mechanism in all cases.
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                                  5. DRUG AND EXCIPIENT PROFILE 
5.1. DRUG PROFILE :                                        (IP, 2007; BP., 2009; Kabir, et al., 
2009) 
5.1.1. ACECLOFENAC:
 
            Aceclofenac is a potent non-steroidal anti-inflammatory drug. Due to its 
preferential cox-2 blockage it has better safety than conventional NSAIDs with 
respect to adverse effects on gastro intestinal and cardiovascular system. 
IUPAC Name          :  2-[(2, 6-Dichlorophenylamino) phenyl] acetoxy acetic acid. 
Description              :  A white to almost white crystalline powder. 
Structure : 
 
Molecular formula:   C16H13Cl2NO4 
Molecular weight:     354.2 
Category              :    Non-steroidal anti inflammatory drug. 
Solubility               : It is practically insoluble in water; soluble in alcohol and methyl  
                                  alcohol; It is freely soluble in acetone and dimethyl formamide. 
Melting point       :  149 - 150ºC 
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Pharmacology: 
 
The mode of action of Aceclofenac is largely based on the inhibition of the 
prostaglandin synthesis. Aceclofenac is a potent inhibitor of the enzyme 
Cyclooxygenase, which is involved in the production of prostaglandins. 
The drug inhibits synthesis of the inflammatory cytokines, interleukin (IL)-1 
and tumor necrosis factor and prostaglandin (PGE2) production. Effects on cell 
adhesion molecular from neurophils have also been noted. In vivo data indicate 
inhibition of Cyclooxygenase (COX-1 and 2) by Aceclofenac in whole blood says, 
with selectivity for COX-2 being evident. 
Aceclofenac has shown stimulatory effects on cartilage matrix synthesis that 
may be linked to the ability of the drug to inhibit IL-1 activity. In vitro data indicate 
stimulation by the drug of synthesis of glycosaminoglycan in osteoarthritic cartilage. 
There is also evidence that Aceclofenac stimulates the synthesis of IL-1 receptor 
antagonist in human articular chondrocytes subjected to inflammatory stimuli and that 
4'-hydroxyaceclofenac has chondroprotective properties attributable to Aceclofenac in 
patients with ankylosing spondylitis. 
Pharmacokinetics: 
Aceclofenac is rapidly and completely absorbed after oral administration, peak 
plasma concentration is reached 1 to 3 hours after an oral dose. The drug is highly 
protein bound. The presence of food does not alter the extent of absorption of 
Aceclofenac but the absorption rate is reduced. It is metabolized to a major metabolite 
4-hydroxy aceclofenac and to a number of other metabolites including 5–hydroxy 
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aceclofenac, 4-hydroxy diclofenac. Renal excretion is the main route of elimination of 
Aceclofenac with 70 to 80 % of an administered dose found in the urine, mainly as 
the glucuronides of Aceclofenac and its metabolites of each dose of Aceclofenac, 
20% is excreted in the faeces. The plasma elimination half life of the drug is 
approximately 4 hours. 
Drug interactions: 
Aceclofenac may increase plasma concentrations of lithium, digoxin and 
methotrexate, increase the activity of anticoagulant, inhibits the activity of diuretics, 
enhance cyclosporine nephrotoxicity and precipitate convulsions when co-administered 
with quinolone antibiotics. Furthermore, hypo or hyperglycemia may result from the 
concomitant administration of Aceclofenac and antidiabetic drugs, although this is 
rare. The co-administration of Aceclofenac with other NSAIDs results in increased 
frequency of adverse event. 
Adverse drug interactions: 
Aceclofenac is well tolerated with, most adverse events being minor and 
reversible and affecting mainly the G.I system. Most common events include 
dyspepsia (7.5%), abdominal pain (6.2%), nausea (1.5%), diarrohoea (1.5%), 
flatulance (0.8%), gastritis (0.6%), constipation (0.5%), vomiting (0.5%), and 
pancreatitis (0.1%). Other adverse effects which is not common such as dizziness 
(1%), vertigo (0.3%), and rare cases of paraesthesia and tremor. 
Dosage and administration: The usual dose of Aceclofenac is 100 mg given twice 
daily by mouth, one tablet in the morning and one in the evening. 
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Storage:  In an air tight container, protected from light. 
Uses: Aceclofenac is used in the treatment of osteoarthritis, rheumatoid arthritis, 
ankylosing spondylitis, dental pain, post operative pain, dysmenorrhoea, acute 
lumbago, musculoskeletal trauma and gonalgia (knee pain). 
5.2. Excipients profile:     
5.2.1. HYPROMELLOSE:                                       (Raymond C. Rowe, 2003)                           
1. Nonproprietary Names: 
 BP: Hypromellose   
 JP: Hydroxypropylmethylcellulose                    
 PhEur: Hypromellosum    
 USP: Hypromellose 
2. Synonyms:  
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
Tylopur. 
3. Chemical Name and CAS Registry Number: 
Cellulose hydroxypropyl methyl ether [9004-65-3] 
4. Molecular Weight: 10,000–1,500,000.  
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5. Structural Formula: 
 
Where R is H, CH3, or CH3CH (OH) CH2 
6. Functional Category: Coating agent; film-former; rate-controlling polymer for 
sustained release; stabilizing agent; suspending agent; tablet binder; viscosity-
increasing agent. 
7. Applications in Pharmaceutical Formulation or Technology: 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, in 
film-coating, and as matrix for use in extended-release tablet formulations.  High-
viscosity grades may be used to retard the release of drugs from a matrix at levels of 
10–80% w/w in tablets and capsules. Depending upon the viscosity grade, 
concentrations of 2-20% w/w are used for film-forming solutions to film-coat tablets. 
Hypromellose at concentrations 0.45-1.0% w/w may be added as a thickening agent to 
vehicles for eye drops and artificial tear solutions. Lower-viscosity grades are used in 
aqueous film-coating solutions, while higher-viscosity grades are used with organic 
solvents.  
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8. Description: Hypromellose is an odorless and tasteless, white or creamy-white 
fibrous or granular powder. 
9. Typical Properties: 
 Acidity/alkalinity            :  pH = 5.5–8.0 for a 1% w/w aqueous solution. 
 Density (bulk)                 :  0.341 g/cm3 
 Density (tapped)             :  0.557 g/cm3 
 Density (true)                  : 1.326 g/cm3 
 Melting Point                  :  browns at 190–200°C; chars at 225–230°C 
              Glass transition temperature is 170-180
o
C   
  Solubility: Soluble in cold water, forming a viscous colloidal solution; 
practically insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures 
of ethanol and dichloromethane, mixtures of methanol and dichloromethane, and 
mixtures of water and alcohol.  
 Viscosity (dynamic): A wide range of viscosity types are commercially 
available. Aqueous solutions are most commonly prepared, although hypromellose 
may also be dissolved in aqueous alcohols such as ethanol and propan-2-ol provided 
the alcohol content is less than 50% w/w. 
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Table 5.1: Various Grades of Hypromellose 
Methocel product USP 28 designation Nominal viscosity (mPa s) 
Methocel K100 Premium LVEP 2208 100 
Methocel K4M Premium 2208 4000 
Methocel K15M Premium 2208 15 000 
Methocel K100M Premium 2208 100 000 
Methocel E4M Premium 2910 4000 
Methocel F50 Premium 2906 50 
Methocel E10M Premium CR 2906 10 000 
Methocel E3 Premium LV 2906 3 
Methocel E5 Premium LV 2906 5 
Methocel E6 Premium LV 2906 6 
Methocel E15 Premium LV 2906 15 
Metolose 60SH 2910 50, 4000, 10 000 
Metolose 65SH 2906 50, 400, 1500, 4000 
Metolose 90SH 2208 100, 400, 4000, 15 000 
 
10. Stability and Storage Conditions: 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity 
of solutions. Hypromellose undergoes a reversible sol–gel transformation upon 
heating and cooling, respectively.  
11. Incompatibilities: 
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts. 
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5.2.2. CARBOXYMETHYLCELLULOSE SODIUM:    (Raymond C. Rowe, 2003)    
1. Nonproprietary Names: 
 BP: Carmellose sodium 
 JP: Carmellose sodium 
 PhEur: Carmellosum natricum 
 USP: Carboxymethylcellulose sodium 
2. Synonyms:  
Cellulose gum; CMC sodium; SCMC; sodium carboxymethylcellulose; 
sodium cellulose glycolate; sodium CMC 
3. Chemical Name and CAS Registry Number:  
Cellulose, carboxymethyl ether, sodium salt [9004-32-4] 
4. Molecular Weight:  90,000–7, 00,000 
5. Structural Formula: 
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6. Functional Category:  
Coating agent; stabilizing agent; suspending agent; tablet and capsule 
disintegrant; tablet binder; viscosity-increasing agent; water-absorbing agent. 
7. Applications in Pharmaceutical Formulation or Technology:  
Carboxymethylcellulose sodium is widely used in oral and topical 
pharmaceutical formulations, primarily for its viscosity-increasing properties. Viscous 
aqueous solutions are used to suspend powders intended for either topical application 
or oral and parenteral administration. Carboxymethylcellulose sodium may also be 
used as a tablet binder and disintegrant and to stabilize emulsions. 
Higher concentrations, usually 3–6%, of the medium-viscosity grade are used 
to produce gels that can be used as the base for applications and pastes; glycols are 
often included in such gels to prevent them drying out.  
Carboxymethylcellulose sodium is additionally one of the main ingredients of 
self-adhesive ostomy, wound care and dermatological patches, where it is used as a 
mucoadhesive and to absorb wound exudate or transepidermal water and sweat. This 
muco-adhesive property is used in products designed to prevent post-surgical tissue 
adhesions; and to localize and modify the release kinetics of active ingredients applied 
to mucous membranes; and for bone repair. Encapsulation with 
carboxymethylcellulose sodium can affect drug protection and delivery. There have 
also been reports of its use as a cytoprotective agent. Carboxymethylcellulose sodium 
is also used in cosmetics, toiletries, surgical prosthetics, and incontinence, personal 
hygiene, and food products. 
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Uses Concentration (%) 
Emulsifying agent 
Gel-forming agent 
Injections 
Oral solutions 
Tablet binder 
0.25–1.0 
3.0–6.0 
0.05–0.75 
0.1–1.0 
1.0–6.0 
8. Description: 
Carboxy methylcellulose sodium occurs as a white to almost white, odorless, 
granular powder. 
9. Typical Properties: 
 Density (bulk)                 :   0.52 g/cm3  
 Density (tapped)             :   0.78 g/cm3  
 Dissociation constant     :    pKa=4.30 
 Melting Point                  :    browns at 227°C; chars at 252°C 
 Moisture Content: Typically contains less than 10% water. However, 
carboxymethylcellulose sodium is hygroscopic and absorbs significant amounts of 
water at temperatures up to 37°C at relative humidities of about 80%.  
 Solubility: Practically insoluble in acetone, ethanol (95%), ether, and toluene. 
Easily dispersed in water at all temperatures, forming clear, colloidal solutions. The 
aqueous solubility varies with the degree of substitution (DS).  
 Viscosity: Various grades of carboxy methylcellulose sodium are 
commercially available that have differing aqueous viscosities. Aqueous 1% w/v 
solutions with viscosities of 5–13,000 mPa‟s (5–13,000 Cps) may be obtained. An 
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increase in concentration results in an increase in aqueous solution viscosity. 
Prolonged heating at high temperatures will depolymerize the gum and permanently 
decrease the viscosity. The viscosity of sodium carboxy methylcellulose solutions is 
fairly stable over a pH range of 4–10. The optimum pH range is neutral.  
10. Stability and Storage Conditions: 
Carboxy methylcellulose sodium is a stable, though hygroscopic material. 
Under high humidity conditions, carboxy methylcellulose sodium can absorb a large 
quantity (>50%) of water.  
Aqueous solutions are stable at pH 2–10; precipitation can occur below pH 2, 
and solution viscosity decreases rapidly above pH 10. Generally, solutions exhibit 
maximum viscosity and stability at pH 7–9. Carboxy methylcellulose sodium may be 
sterilized in the dry state by maintaining it at a temperature of 160°C for 1 hour. 
However, this process results in a significant decrease in viscosity and some 
deterioration in the properties of solutions prepared from the sterilized material. 
Aqueous solutions may similarly be sterilized by heating, although this also 
results in some reduction in viscosity. After autoclaving, viscosity is reduced by about 
25%, but this reduction is less marked than for solutions prepared from material 
sterilized in the dry state. The extent of the reduction is dependent on the molecular 
weight and degree of substitution; higher molecular weight grades generally undergo 
a greater percentage reduction in viscosity. Sterilization of solutions by gamma 
irradiation also results in a reduction in viscosity. Aqueous solutions stored for 
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prolonged periods should contain an antimicrobial preservative. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
11. Incompatibilities: 
Carboxymethylcellulose sodium is incompatible with strongly acidic solutions 
and with the soluble salts of iron and some other metals, such as aluminum, mercury, 
and zinc. Precipitation may occur at pH <2, and also when it is mixed with ethanol 
(95%). Carboxymethylcellulose sodium forms complex coacervates with gelatin and 
pectin. It also forms a complex with collagen and is capable of precipitating certain 
positively charged proteins. 
5.2.3. Xanthan Gum:                                                       (Raymond C. R., et al., 2003) 
Nonproprietary Names: 
BP : Xanthan gum 
PhEur : Xanthani gummi 
USPNF : Xanthan gum 
Synonyms: 
      Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; Vanzan 
NF; Xantural 
Chemical name and CAS registry number: 
Xanthan gum [11138-66-2] 
Molecular weight: 
Approximately 20,00,000. 
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Functional category: 
Stabilizing agent; suspending agent and viscosity-increasing agent.   
Description: 
Xanthan gum occurs as a cream- or white-colored, odorless, free-flowing,   
fine powder. 
Solubility:  
           It is practically insoluble in ethanol and ether, soluble in cold or warm water. 
Viscosity (dynamic): 
           1200-1600 m Pa‟s (1200–1600 Cps) for  1% w/v aqueous solution at 25°C. 
Applications in pharmaceutical formulation or technology: 
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics and foods as a suspending and stabilizing agent. It is also used as a 
thickening and emulsifying agent. It is nontoxic, compatible with most other 
pharmaceutical ingredients, and has good stability and viscosity properties over a 
wide pH and temperature range. When xanthan gum is mixed with certain inorganic 
suspending agents, such as magnesium aluminum silicate, or organic gums, 
synergistic rheological effects occur. It is used as for preparation of sustained release 
matrix tablets and also used as thickening agent in shampoo. 
Stability and storage conditions: 
Bulk material should be stored in a well closed container in a cool, dry place.  
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5.2.4. Cellulose, Microcrystalline:                                  (Raymond C. R., et al., 2003) 
Nonproprietary names: 
BP : Microcrystalline cellulose 
JP : Microcrystalline cellulose 
PhEur : Cellulosum microcristallinum 
USPNF : Microcrystalline cellulose 
Synonyms: 
Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; 
E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
Chemical name and CAS registry number: 
Cellulose [9004-34-6] 
Molecular weight: 
Approximately 36,000 
Structural formula: 
 
Functional category: 
Adsorbent; suspending agent; tablet and capsule diluents; tablet disintegrant. 
Description: 
Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
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particles. It is commercially available in different particle sizes and moisture grades 
that have different properties and applications. 
Moisture content: 
 Typically less than 5% w/w. However, different grades may contain varying   
amounts of water. Microcrystalline cellulose is hygroscopic.  
Solubility:  
 Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in 
water, dilute acids and most organic solvents. 
Applications in pharmaceutical formulation or technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as 
binder/diluents in oral tablet and capsule formulations where it is used in both wet-
granulation and direct compression processes. In addition to its use as binder/diluents, 
microcrystalline cellulose also has some lubricant and disintegrant properties that 
make it useful in tableting. 
 
Use                                                                     Concentration (%) 
Adsorbent                                                                20–90 
Antiadherent                                                             5–20 
Capsule binder/diluent                                               20–90 
Tablet disintegrant                                                     5–15 
Tablet binder/diluent                                                 20–90 
Stability and storage conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
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5.2.5. Talc:                                                                        (Raymond C. R., et al., 2003) 
Nonproprietary names: 
BP : Purified talc 
JP : Talc 
PhEur : Talcum 
USPNF : Talc 
Synonyms:  
 Purified chalk, altalc, powdered talc and soapstone 
Chemical name and CAS registry number: 
Talc [14807-96-6] 
Description: 
A very fine, white to grayish white, impalpable, odorless crystalline powder, 
Unctuous, adheres readily to skin, soft to touch and free from granules. 
Empirical formula:             Mg6 (Si2O5)4(OH)4 
Functional category: 
            Tablet, capsule it can use as a lubricant and diluents. During compression used 
as glidant and anticaking agent 
Solubility         :   Insoluble in water, organic solvents, dilute acids and alkalis. 
Storage conditions: Stable, Preserve in a well-closed container in a cool, dry place. 
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5.2.6. Magnesium stearate:                                              (Raymond C.R., et al., 2003) 
Nonproprietary names: 
BP : Magnesium stearate 
JP : Magnesium stearate 
PhEur : Magnesii stearas 
USPNF : Magnesium stearate  
Synonyms :   Magnesium octa decanoate, Magnesium salt. 
Chemical name and CAS registry number: 
Octa decanoic acid magnesium salt [557-04-0] 
Functional category : Tablet and capsule lubricant 
Empirical formula :   C36H70MgO4 
Molecular weight :  591.3 
Structure : 
                                         CH3 (CH2)16 COO                           
                                                                               Mg    
                                         CH3 (CH2)16 COO 
Description:      
 It is a fine, white, precipitated or milled, impalpable powder of low bulk 
density and having a faint odor of stearic acid, characteristic taste.  
 Solubility:  
 It is insoluble in water, ethanol and ether. It can slightly soluble in warm 
ethanol and benzene.        
 Stability and storage conditions: 
  Stable, Store in a well closed container in a cool, dry place.                    
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5.2.7. Povidone:                                                                (Raymond C. R., et al., 2003) 
Nonproprietary names: 
   BP       : Povidone      
            JP        : Povidone            
PhEur    : Povidonum                         
USP       : Povidone 
Synonyms: 
 E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl) 
ethylene]; polyvidone; polyvinyl pyrrolidone; 1-vinyl-2-pyrrolidinone polymer. 
Chemical name and CAS registry number: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Empirical formula and molecular weight: 
(C6H9NO) n and 2500-30,00,000 respectively 
K-value                                                approximate molecular weight 
12                                                             2500 
15                                                             8 000 
25                                                            30 000 
30                                                            50 000 
60                                                            400 000 
90                                                            1 000 000 
120                                                          3 000 000 
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Structural formula: 
 
Functional category: Disintegrant; dissolution aid; suspending agent; tablet binder. 
Description:  Povidone occurs as a fine, white to creamy-white colored, odorless,    
hygroscopic powder. 
Moisture content:   
 Povidone is very hygroscopic, significant amounts of moisture being absorbed 
at low relative humidity.  
Solubility:   
            Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol and 
water; practically insoluble in ether, hydrocarbons and mineral oil.  
Viscosity (dynamic):   
 The viscosity of aqueous povidone solutions depends on both the 
concentration and the molecular weight of the polymer employed.  
Applications in pharmaceutical formulation or technology: 
Although povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tableting, povidone solutions are used as 
binders in wet granulation processes. Povidone is also added to powder blends in the 
dry form and granulated in situ by the addition of water, alcohol or hydro alcoholic 
solutions.  
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                          Use                                                                     Concentration (%) 
Carrier for drugs                                                                  10–25 
  Dispersing agent                                                                 Up to 5 
Eye drops                                                                            2–10 
  Suspending agent                                                               Up to 5 
 Tablet binder, tablet diluents or coating agent                          0.5–5 
Stability and storage conditions: 
 Povidone darkens to some extent on heating at 150°C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–130°C; 
steam sterilization of an aqueous solution does not alter its properties.  
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6.MATERIALS AND EQUIPMENTS 
 
Table 6.1: List of materials with source 
S.No. Name of Ingredients Name of supplier 
1 Aceclofenac Tristar formulation Pvt. Ltd., Puducherry. 
2 HPMC K15M Tristar formulation Pvt. Ltd., Puducherry. 
3 Carboxy methylcellulose Tristar formulation Pvt. Ltd., Puducherry. 
4 Xanthan gum Nickon laboratories Pvt. Ltd., Puducherry. 
5 Microcrystalline cellulose Nickon laboratories Pvt. Ltd., Puducherry. 
6 Polyvinyl pyrrolidone  Nickon laboratories Pvt. Ltd., Puducherry. 
7 Magnesium stearate Loba chemie Pvt.Ltd., Mumbai. 
8 Talc Loba chemie Pvt.Ltd., Mumbai. 
9 Hydrochloric acid S d fine-chem limited., Mumbai. 
10 Methanol Qualigens fine chemicals, Mumbai. 
11 Acetone Loba chemie Pvt.Ltd., Mumbai. 
12 Sodium hydroxide S d fine-chem limited., Mumbai. 
13 Ethanol(95%) S d fine-chem limited., Mumbai. 
14 Chloroform Loba chemie Pvt.Ltd., Mumbai. 
15 Isopropyl alcohol Qualigens fine chemicals, Mumbai. 
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6.2 Equipments used: 
Table 6.2: List of equipments with model/make 
S.No. Equipment Model/ Make 
   1 Electronic balance Shimadzu BL-220H, Japan. 
   2 Bulk density apparatus Indolabs VTAP/MATIC-II, Chennai. 
   3 Standard sieves Jayant scientific, India. 
   4 Hot air oven Precision scientific Co., Chennai. 
   5 
Sixteen punch tablet compression 
machine 
Cadmach, Ahmadabad, India. 
  6 Friability apparatus Veego scientific VFT-DV, Mumbai. 
  7 Hardness tester Monsanto 
  8 Vernier caliper Indolabs, Mitutoyo. 
  9 Humidity chamber Labtech, Ambala. 
 10 USP dissolution test apparatus 
Type I 
Veego scientific VDA-8DR, Mumbai. 
 11 UV spectrophotometer Elico-SL 159 UV-Visible 
spectrophotometer, Japan. 
 12 FTIR spectrophotometer Perkin elmer-Pharmaspec-1. 
 13 Differential scanning calorimeter Shimadzu DSC 60, Japan. 
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7.EXPERIMENTAL WORK 
 
7.1. PREFORMULATION STUDIES: 
7.1.1. Characterization of Aceclofenac: 
7.1.1.1. Organoleptic properties: (Lachman L, et al., 1991; Banker G.S., and Rhodes 
C.T., 2009) 
   The colour, odour and taste of the drug were recorded using descriptive 
terminology. 
7.1.1.2. IR spectrum interpretation:       (IP, 2007; Silverstein R.M., Webster F.X., 
2003) 
The infrared spectrum of pure Aceclofenac was recorded and spectral analysis 
was done. The dry sample of the drug was thoroughly mixed with potassium 
hydrobromide and directly placed in the sample holder. 
7.1.1. Loss on drying:                               (IP., 2007) 
  Loss on drying is the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
condition. The test can be carried out on the well mixed sample of the substance. 
                      Initial weight of substance – Final weight of substance 
  Loss on drying = --------------------------------------------------------------------       x 100 
 Initial weight of substance 
 
7.1.1.4. Melting point:                                  (IP, 2007) 
  Melting point of the drug was determined by capillary tube method. 
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7.1.1.5. Solubility study:                               (IP, 2007) 
 The solubility of drug was recorded by using various descriptive terminology 
specified in Indian Pharmacopoeia, 2007.  
7.1.2. Analytical methods:  
7.1.2.1. Determination of  max:                                 (IP., 2007) 
Preparation of stock solution:  
 50 mg of Aceclofenac was accurately weighed and transferred to a 50 ml 
volumetric flask. It was dissolved in sufficient amount of Methanol and volume was 
made upto 50 ml with Methanol. Exactly 10ml of the stock solution was pipetted out 
and was diluted to 100 ml with Methanol (10 g/ml). The spectrum was recorded in 
the range of 220-370 nm.  
Preparation of standard curve of Aceclofenac:                               (IP, 2007) 
i. By using in 0.1N hydrochloric acid: 
   A standard curve was prepared by dissolving 50 mg of Aceclofenac 50 
ml of   0.1N HCl. In the stock solution 1 ml withdrawn and diluted to 25 ml of 0.1N 
HCl . It was further diluted with 0.1N HCl to get the solution in the concentration 
range of 0-20 g/ml. The absorbance values were determined at 272.5 nm. 
ii. By  using in phosphate buffer pH  7.4:  
    A standard curve was prepared by dissolving 50 mg of Aceclofenac in 
methanol and shake upto drug dissolved, then finally make upto 50 ml with pH 7.4 
phosphate buffer. In the stock solution 1 ml withdrawn and diluted to 25 ml with 
phosphate buffer. It was further diluted to get the solution in the concentration range 
0-20g/ml. The absorbance values were determined at 274 nm.  
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7.1.3. Compatibility testing of drug with polymer: (IP, 2007; Aulton M.E., 2007; 
Silverstein R.M, Webster F.X., 2003; Skoog D.A.,et.al.,1996) 
 The proper design and formulation of a dosage form requires consideration of 
the physical, chemical and biological characteristics of all drug substances and 
excipients to be used in the fabricating the product. Each polymer used in the 
formulations was blended with the drug levels that are realistic with respect to the 
final dosage form. Each polymer was thoroughly blended with drug to increase drug - 
polymer molecular contacts to accelerate the reactions if possible. 
 
7.1.3.  Fourier transform Infra-Red (FTIR) spectroscopy:  
  FTIR study was carried out to check compatibility of drug with polymers. 
Infrared spectrum of Aceclofenac was determined on Fourier transform Infrared 
Spectrophotometer using KBr dispersion method. The base line correction was done 
using dried potassium bromide. Then the spectrum of dried mixture of drug and 
potassium bromide was run followed by drug with various polymers by using FTIR 
spectrophotometer. The absorption maximums in spectrum obtained with the 
substance being examined correspond in position and relative intensity to those in the 
reference spectrum.  
7.1.4.  Differential scanning calorimetry (DSC): 
 Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC study was performed on pure drug, and polymers, drug+HPMC K15M, 
drug+Carboxy methylcellulose and drug+ Xathan gum. The study was carried out 
using a Shimadzu. The 2 mg of sample were heated in a hermetically sealed 
aluminum pans in the temperature range of 25-300ºC at heating rate of 10ºC /min 
under nitrogen flow of 30ml/min.  
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7.1.4. Formulation of aceclofenac sustained release matrix tablets: (Sharma A., et 
al., 2009; Bandhalarajan S., et al., 2011) 
Table 7.1: Composition of Aceclofenac matrix tablets 
Ingredients(mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Aceclofenac 200 200 200 200 200 200 200 200 200 
HPMC K15M  40 60 80 - - - - - - 
Carboxy methyl 
cellulose 
- - - 40 60 80 - - - 
Xanthan gum  - - - - - - 40 60 80 
Microcrystalline- 
cellulose  
65 45 25 65 45 25 65 45 25 
Polyvinyl pyrrolidone 30 30 30 30 30 30 30 30 30 
Isopropyl alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
Magnesium stearate 10 10 10 10 10 10 10 10 10 
Talc 5 5 5 5 5 5 5 5 5 
Total weight 350 350 350 350 350 350 350 350 350 
 
7.1.5. Preparation of granules:      (Prema R., et al., 2010) 
           Granules for aceclofenac matrix tablets were prepared by wet granulation 
technique using various percentages of HPMC K15M, carboxy methyl cellulose and 
xanthan gum as release retardant polymers. All the powders passed through sieve 
No.80. The required quantity of drug, various polymers and other ingredients were 
mixed thoroughly and a sufficient volume of granulating agent (isopropyl alcoholic 
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solution of polyvinyl pyrrolidone) was added slowly. After enough cohesiveness was 
obtained, the wet mass was sieved through sieve No.8. The granules were dried at 
60 C for 30 minutes and then the dried granules were passed through sieve No.16.  
Talc and magnesium stearate were finally added as a glidant and lubricant 
respectively.   
7.1.6. Evaluation of granules: 
7.1.6.1. Angle of repose:            (Subramanyam C.V.S., 2009) 
The angle of repose of granules was determined by the funnel method. The 
accurately weighed granules were taken in a funnel. The height of the funnel was 
adjusted in such a way that the tip of the funnel just touched the apex of the heap of 
the granules. The granules were allowed to flow through the funnel freely onto the 
surface. The diameter of the granules cone was measured and angle of repose was 
calculated using the following equation. 
   tan   = h/r 
Where, h and r are the height and radius of the granules cone respectively.       
                      Table 7.2: Standard values of angle of repose ( )  
S. No. Flowability Angle of repose 
1 Excellent <25 
2 Good 25-30 
3 Passable* 30-40 
4 Poor 37-45 
5 Very poor >45 
* Adding glidant for improving flow 
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7.1.6.2. Loose bulk density:                                          (Raghuram R. K., et al., 2003)                           
An accurately weighed granules from each formulation was lightly shaken to 
break any agglomerates formed and it was introduced in to a measuring cylinder. The 
volume occupied by the granules was measured which gave bulk volume. The loose 
bulk density of granules was determined using the following formula.  
Loose bulk density = Total weight of granules / Total volume of granules 
7.1.6.3. Tapped bulk density:                                        (Raghuram R.K., et al., 2003)                                                 
An accurately weighed granules from each formula was lightly shaken to 
break any agglomerates formed and it was introduced into a measuring cylinder. The 
measuring cylinder was tapped until no further change in volume was noted which 
gave the tapped volume. The TBD of granules was determined by the following 
formula.  
Tapped bulk density =   Total weight of granules/ Tapped volume                                 
7.1.6.4. Hausner ratio:                                                                   (Aulton M.E., 2007) 
Hausner ratio is the ratio between tapped density and bulk density. Hausner 
ratio less than 1.25 indicates good flow properties while Hausner ratio greater than 
1.25 shows poor flow of granules. 
7.1.6.5. Carr’s compressibility index:                          (Aulton M.E., 2007)                    
  It is a simple index that can be determined on small quantities of granules. In 
theory, the less compressible a material the more flowable it is.  
             The compressibility index of the granules was determined using following 
formula.    
 Carr‟s compressibility index (%)   = [(TBD-LBD)/ TBD] ×100     
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Table 7.3: Standard values of carr‟s index 
Carr’s index % Flowability 
5-15 Excellent 
12-16 Good 
18-21 Fairly acceptable 
23-35 Poor 
33-38 Very poor 
< 40 Very very poor 
                                     
7.2. Preparation of tablets:              (Bandhalarajan S., et al., 2011) 
            The evaluation of granules showed excellent flow properties. The granules 
were compressed into tablets on 16 station rotary tablet compression machine using 
11 mm round, biconcave punches. The compressed tablets were evaluated for various 
parameters viz. appearance, thickness, diameter, hardness, friability, weight variation, 
drug content and in vitro drug release studies.  
7.3. Evaluation of Sustained release matrix tablet of Aceclofenac:       
7.3.1. Appearance:      (Lachman L., et al., 1991; Bankar G.S. and Rhodes C.T., 
2009) 
The tablets were visually observed for capping, chipping, and lamination. 
7.3.2. Dimension (thickness and diameter):                    (Lachman L., et al., 1991) 
The thickness and diameter of tablets were important for uniformity of tablet 
size. The thickness and diameter of the tablets was determined using a vernier caliper. 
Ten tablets from each type of formulation were used and average values were 
calculated. 
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7.3.3. Weight variation test:       (IP, 2007)  
For weight variation, 20 tablets of each type of formulation were weighed 
individually on an electronic balance, average weight was calculated and individual 
tablet weight was then compared with the average value to find out the deviation in 
weight. 
Table 7.4: Specifications of %Weight variation allowed in tablets as per IP. 
S. No Average Weight of tablet % Deviation 
1. 80 mg or less 10 
2 More than 80 but less than 250 mg 7.5 
3 250 mg or more 5 
 
 
7.3.4. Hardness:  
  For each type of formulation, the hardness value of 10 tablets was determined 
using Monsanto hardness tester.  
7.3.5. Percentage friability :                                  (Lachman L., et al., 1991; Banker 
G.S. and Rhodes C.T., 2009) 
Friability is the measure of tablet strength. This test subjects a number of 
tablets to the combined effect of shock abrasion by utilizing a plastic chamber which 
revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in each 
revolution. A sample of preweighed tablets was placed in Roche friabilator which was 
then operated for 100 revolutions. The tablets were then dedusted and reweighed. A 
loss of less than 1 % in weight is generally considered acceptable. Percent friability 
(% F) was calculated as follows, 
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7.3.6. Content uniformity:       (Krishna R. Gupta, et al., 2011; IP, 2007) 
  Content uniformity was determined by accurately weighing 20 tablets and 
crushing them in mortar with the help of a pestle. Then an accurately weighed 
quantity of powder equivalent to 25 mg of drug was transferred to a 50 ml volumetric 
flask. Then added few ml of methanol and made upto 50ml with methanol. The 
solution was filtered through whatmann filter paper. 5 ml of the filtrate was diluted to 
50 ml with Methanol. Then   3 ml of the resulting solution was again diluted to 10 ml 
with Methanol. The absorbance of the resulting 15 g/ml solution was recorded at 
274nm. 
7.3.7. In-vitro dissolution studies: (IP, 2007; Bandhalarajan S., et al., 2011; 
 Yeole P.G., et al., 2006) 
The in-vitro dissolution studies were performed using USP type I dissolution 
apparatus at 50rpm. Dissolution test was carried out for a total period of 8 hours using 
0.1N HCl (pH 1.2) solution (900 ml) as dissolution medium at 37 ± 0.5° for first 2 h, 
and pH 7.4 phosphate buffer solution (900 ml) for the rest of the period An aliquot 
(5ml) was withdrawn at specific time intervals and absorbance was determined by 
U.V. spectrophotometer at 274nm. The release studies were conducted in triplicate. 
7.3.8. Data Analysis (Curve Fitting Analysis): (Brahmankar D.M and Jaiswal S.B., 
2009; Chandira, et al., 2009)
 
 
  To analyze the mechanism of the drug release rate kinetics of the dosage form, 
the data obtained were graphed as: 
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i. Cumulative percentage drug released Vs Time (In-vitro drug release plots) 
ii. Cumulative percentage drug released Vs Square root of time (Higuchi‟s plots) 
iii. Log cumulative percentage drug remaining Vs Time (First order plots) 
iv. Log percentage drug released Vs Log time (Peppas plots) 
Higuchi release model: 
 To study the Higuchi release kinetics, the release rate data was fitted to the 
following equation.    F = K.t ½ 
Where,  „F‟ is the amount of drug release, 
„K‟ is the release rate constant, and „t‟ is the release time. 
When the data is plotted as accumulative drug released versus square root of time, 
yields a straight line, indicating that the drug was released by diffusion mechanism. 
The slope is equal to „K‟. 
Korsmeyer and Peppas release model: 
  The release rate data were fitted to the following equation, 
Mt / M∞   = K. tn 
  Where,   Mt / M∞ is the fraction of drug release,  
      „K‟ is the release constant, 
      „t‟ is the release time, 
  „n‟ is the diffusional exponent for the drug release that dependent on the shape 
of the matrix dosage form. 
  When the data is plotted as Log of released versus Log time, yields as straight 
line with a slope equal to „n‟ and the „K‟ can be obtained from Y – intercept. 
Aceclofenac sustained Release Tablets      EXPERIMENTAL WORK                 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 88 
  For non- Fickian release the „n‟ values falls between 0.5 and 1.0 while for 
Fickian (case I) diffusion n= 0.5 and zero order release ( case II transport) n= 1.0. 
Zero order release rate kinetics: 
  To study the zero-order release kinetics the release rate data are fitted to the 
following equation. 
F = Kt 
     Where „F‟ is the fraction of drug release, 
      „K‟ is the release rate constant and  
      „t‟ is the release time. 
  When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys zero-order release kinetics, with a slope equal to K.  
7.4. Stability study:           (Carstensen J. T., et al., 2008; Manavalan R, et al., 2008)  
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted.  
ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25 C ± 2 C at 60% RH ± 5% for 12 Months  
 Accelerated Testing: 40 C ± 2 C at 75% RH ± 5% for 6 Months  
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In present study the selected formulation F9 exposure  up to 3 months stability 
studies at accelerated condition (40 C ± 2 C
 
at 75% RH ± 5% RH) to find out the 
effect of aging on hardness, drug content and in vitro drug release.  
Stability studies were carried out at accelerated condition (40 C ± 2 C
 
at 75% 
RH ± 5% RH) for the optimized formulation F9. The matrix tablets were stored at 
40 C ± 2 C at 75% RH ± 5% RH for accelerated temperature in closely packed with 
aluminium foil for 3 months. The samples were withdrawn after periods of 1
st
 month, 
2
nd
 month and 3
rd
 month. The samples were analyzed for its hardness, drug content 
and in vitro drug release.    
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8. RESULTS AND DISCUSSION 
 
8.1. Preformulation Parameters: 
8.1.1. Characterization of Aceclofenac: 
 8.1.1.1. Organoleptic properties: 
Odourless, white or almost white crystalline powder. 
8.1.1.2. IR spectrum interpretation: 
 
Figure 8.1: IR spectra of Aceclofenac 
8.1.1.3. Loss on drying: 
            The percentage loss on drying for Aceclofenac was found to be 0.1%. 
8.1.1.4. Melting point: 
Melting point values of Aceclofenac sample was found to be 152
0
C, 153
0
C 
and 152
0
C. The reported melting point Average for Aceclofenac is 152.33
0
C. Hence, 
experimental values are in good agreement with official values. 
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8.1.1.5. Solubility study: 
Table 8.1: Solubility of aceclofenac in different solvents 
 
8.1.2. λmax Determination: 
8.1.2.1. λmax Determination in 0.1N HCl: 
The absorption maximum for Aceclofenac was found to be 272.5 nm. 
 
 
Figure 8.2:  λ max observed for Aceclofenac in 0.1N HCl 
S.No. Solvent used Inference 
1 Distilled water insoluble 
2 Ethanol 95% soluble 
3 Methanol soluble 
4 0.1N HCl very slightly  soluble 
5 0.1N NaOH insoluble 
6 Acetone freely soluble 
7 pH 7.4 phosphate buffer slightly soluble 
8 Chloroform sparingly soluble 
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8.1.2.2. λmax Determination in Phosphate buffer pH 7.4:  
  The absorption maximum for Aceclofenac was found to be 274 nm. 
 
 
Figure 8.3:  λ max observed for Aceclofenac in Phosphate buffer pH 7.4 
8.1.2.3. Preparation of standard curve of Aceclofenac: 
i. By using in 0.1N HCl: 
UV absorption spectrum of Aceclofenac in 0.1N HCl shows λ max at 
272.5 nm. Absorbance obtained for various concentrations of Aceclofenac 0.1N 
HCl in are given in table 8.2. The graph of absorbance vs. concentration for 
Aceclofenac was found to be linear in the concentration range of 4 – 20 μg /ml.  
 
Table 8.2: Data of concentration and absorbance for Aceclofenac in 0.1N HCl 
S.No. Concentration (µg/ml) Absorbance  
1 0 0.000 
2 4 0.061 
3 8 0.124 
4 12 0.183 
5 16 0.245 
6 20 0.306 
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Figure 8.4: Calibration Curve of Aceclofenac in 0.1N HCl 
Table 8.3:  Data for Calibration Curve Parameter of 0.1N HCl 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope  0.01529 
3 Intercept 0.00024 
ii. By using in Phosphate buffer pH 7.4: 
UV absorption spectrum of Aceclofenac in Phosphate buffer pH 7.4 
shows λ max at 275 nm. Absorbance obtained from various concentrations of 
Aceclofenac Phosphate buffer pH 7.4 is are given in table 8.4. The graph of 
absorbance vs concentration for Aceclofenac was found to be linear in the 
concentration range of 4 – 20 μg/ml.  
Table 8.4: Concentration and absorbance for Aceclofenac in Phosphate buffer pH 7.4 
                
 
 
 
 
S. No. 
Concentration 
(µg/ml) 
Absorbance 
1 0 0.000 
2 4 0.146 
3 8 0.291 
4 12 0.432 
5 16 0.575 
6 20 0.715 
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Figure 8.5: Calibration curve of Aceclofenac in Phosphate buffer pH 7.4 
      Table 8.5:  Data for Calibration Curve Parameter of Phosphate buffer pH 7.4 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9999 
2 Slope  0.03574 
3 Intercept 0.00248 
8.1.2.4. Percentage purity of pure Drug: 
The percentage purity of drug was calculated by using calibration graph 
method (least square method). 
Table 8.6:  Percentage purity of pure drug 
 
 
The reported percentage purity for Aceclofenac is 99 to 101% (Indian 
Pharmacopoeia 2007). 
 
 
S.No. Percentage purity (%) Avg. percentage purity (%) 
1 98.32  
99.69±1.21 2 100.16 
3 100.60 
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8.1.3. Compatibility testing of drug with polymer: 
8.1.3.1. Fourier transform Infra-Red (FTIR) spectra’s: 
  
Figure 8.6: IR spectra of Aceclofenac 
 
 
 
Figure 8.7: IR spectra of Aceclofenac and HPMC K15M 
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Figure 8.8: IR spectra of Aceclofenac and Carboxy methyl cellulose 
 
 
Figure 8.9:  IR spectra of Aceclofenac and Xanthan gum 
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FTIR spectroscopy was used to ensure that no chemical interaction between 
the drugs and polymers had occurred. From the FTIR spectral Figures 8.6 to 8.9 
interpretations the following result was obtained. The FTIR of Aceclofenac and 
combination of polymers shows intense band in the table as follows. 
Table 8.7: IR peaks of functional groups (cm
-1
) 
Sr. 
No 
Name of the 
ingredient 
-C = O -COOH -NH -OH 
1. Aceclofenac 1149.47 1771.26 1589.20 1055.71 
2. 
Aceclofenac and 
HPMC K15M 
1148.56 1771.46 1589.49 1054.72 
3. 
Aceclofenac and 
Carboxy methyl 
cellulose 
1148.11 1771.01 1589.50 1055.56 
4. 
Aceclofenac and 
Xanthan gum 
1151.56 1771.37 1589.42 1055.57 
 
8.1.3.2. Differential Scanning Calorimetry (DSC): 
The compatibility and interactions between drugs and polymer were checked 
using DSC, results obtained were shown in Figure 8.10 to 8.13. 
 
 
Figure 8.10: Differential Scanning Calorimetry analysis of Aceclofenac. 
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Figure 8.11: Differential Scanning Calorimetry Analysis of Aceclofenac and 
                          HPMC K15M. 
 
 
 
 
 
 
Figure 8.12: Differential Scanning Calorimetry Analysis of Aceclofenac and 
      Carboxy methyl cellulose. 
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Figure 8.13: Differential Scanning Calorimetry Analysis of Aceclofenac and 
       Xanthan gum. 
 
Table 8.8:  Data of DSC thermogram parameters 
    
        DSC thermogram showed that there was no any major difference in onset 
temperature and peak temperature, when compared with pure drug‟s thermogram 
interaction was found between drug and polymers. 
8.2. Evaluation of blended granules: 
The blended granules of different formulation were evaluated for angle of 
repose, loose bulk density, tapped bulk density, compressibility index and Hausner 
ratio. The results of these evaluations were as follows: - 
 
 
S.No. 
Name of ingredients and physical   mixtures 
used in formulation 
Temperature at which peak 
obtained 
1. Aceclofenac 158.3
0
C 
2. Aceclofenac  and HPMC K15M 158.7
0
C 
3. Aceclofenac  and Carboxy methyl cellulose 155.3
0
C 
4. Aceclofenac  and  Xanthan gum 152
0
C 
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8.2.1. Angle of repose: 
            Angle of repose ranged from 21.52
°
± 1.03 to 24.92
°
± 0.78. The results were 
found to be below 25
o 
and hence the blend was found to have excellent flowability. 
(Table 8.9). 
8.2.2. Loose bulk density and tapped density: 
            Bulk and tapped densities are used for the measurement of Compressibility 
index. The LBD and TBD ranged from 0.455 ± 0.00 to 0.500 ± 0.00 g/ml; and 0.526 
± 0.00 to 0.588 ± 0.00 g/ml respectively. (Table 8.9). 
Table 8.9: Flow properties of granules 
Formulation 
code 
Angle of 
repose (
o
)* 
Loose bulk 
density 
(g/ml)* 
Tapped 
bulk density 
(g/ml)* 
Hausner’s 
ratio* 
Carr’s 
index (%)* 
F1 21.52±1.03 0.476±0.00 0.556±0.00 1.17±0.00 14.286±0.00 
F2 22.34±0.49 0.500±0.00 0.588±0.00 1.18±0.00 15.000±0.00 
F3 24.72±0.51 0.455±0.00 0.526±0.00 1.16±0.00 13.636±0.00 
F4 24.92±0.78 0.500±0.00 0.588±0.00 1.18±0.00 15.000±0.00 
F5 22.27±2.30 0.476±0.00 0.556±0.00 1.17±0.00 14.286±0.00 
F6 24.04±1.62 0.476±0.00 0.556±0.00 1.17±0.00 14.286±0.00 
F7 24.72±0.51 0.500±0.00 0.588±0.00 1.18±0.00 15.000±0.00 
F8 24.04±1.62 0.455±0.00 0.526±0.00 1.16±0.00 13.636±0.00 
F9 22.42±2.40 0.500±0.00 0.588±0.00 1.18±0.00 15.000±0.00 
*All the values are expressed as mean± SE, n=3. 
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8.2.3. Compressibility index (Carr’s index): 
 The compressibility index (%) ranged from 13.636 ± 0.00 to 15.000 ± 0.00 
(Table 8.9). The blend was found to have excellent flowing property as the result were 
found to be below 15%.  
8.2.4. Hausner ratio: 
The Hausner ratio ranged from 1.16 ± 0.00 to 1.18 ± 0.00, (Table 8.9). The 
result indicates the free flowing properties of the granules. 
8.3. Evaluation of sustanied release matrix tablets: 
8.3.1. Appearance: 
The tablets were observed visually and did not show any defect such as 
capping, chipping and lamination. 
8.3.2. Physical characteristics:  
The physical characteristic of  Aceclofenac sustained release matrix tablets         
(F1 to F9) such as thickness, diameter, hardness, friability, weight variation and drug 
content were determined and results of the formulations (F1 to F9) found to be within 
the limits specified in official books.  
8.3.3. Dimension (Thickness and Diameter): 
Thickness and diameter specifications may be set on an individual product 
basis. Excessive variation in the tablet thickness and diameter can result in problems 
with packaging as well as consumer acceptance. The size (diameter) of the tablets of 
all formulations was found to be 4.39±0.06 to 4.48±0.08 mm. 
8.3.4. Tablet Hardness:  
A difference in tablet hardness reflects difference in tablet density and 
porosity. In which turn are supposed to result in different release pattern of the drug 
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by affecting the rate of penetration of dissolution fluid at the surface of the tablet and 
formation of gel barrier. The hardness of tablets was found to be in the range of 
7.65±0.58 kg/cm
2 
to 8.05±0.50kg/cm
2
. This indicates good tablet strength.  
8.3.5. Percent Friability: 
Percentage friability of all the formulations was found between 0.043 to 
0.100%. This indicated good handling property of the prepared SR tablet. 
8.3.6. Weight Variation: 
A tablet is designed to contain a specific amount of drug. When the average 
mass of the tablet is 350 mg the pharmacopoeial limit for percentage deviation is ± 5 
%. The percentage deviation from average tablet weight for all the tablet was found to 
be within the specified limits and hence all formulations complied with the test for 
weight variation according to the pharmacopeial specifications. 
Table 8.10: Physico-Chemical Characterization of Aceclofenac SR Tablets 
 
F. 
Code 
 
Thickness 
(mm)* 
Hardness 
(kg/cm
2
)* 
Friability 
(%) 
Weight 
variation 
(mg) 
Drug 
content 
(%w/w)**
 
F1 4.42±0.06    7.80±0.59 0.057 351.40±2.26 99.48±0.45 
F2 4.41±0.04 7.75±0.63 0.071 352.15±2.92 99.22±0.56 
F3 4.42±0.07 7.70±0.54 0.085 350.10±2.77 99.61±0.69 
F4 4.48±0.08 8.05±0.50 0.100 352.05±2.39 100.21±1.09 
F5   4.39±0.06 7.85±0.34 0.057 353.05±2.84 99.78±1.05 
F6 4.41±0.02 7.65±0.58 0.071 351.55±3.02 99.83±1.41 
F7 4.44±0.08 7.80±0.48 0.071 352.60±2.39 100.61±0.35 
F8 4.43±0.07 7.95±0.55 0.043 352.75±2.92 99.88±0.87 
F9 4.46±0.02 7.85±0.41 0.043 351.75±2.95 98.90±0.65 
 
 
*All the values are expressed as mean± SE, n=3 
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8.3.7. Drug content of Aceclofenac: 
The content of active ingredients in the formulation was found to be between 
98.90±0.65 to 100.61±0.35 % w/w, which is within the specified limit as per Indian 
Pharmacopoeia 1996 (i.e. 90-110% w/w). 
 
 
8.3.8. In-Vitro Dissolution Studies: 
Table 8.11: In-vitro release drug profile of formulation F1 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 08.07±1.03 16.14 4.00 0.50 
2 15.13±0.90 30.26 7.75 0.97 
3 27.85±0.57 55.70 12.27 1.67 
4 43.80±1.59 87.60 18.14 2.35 
5 58.16±0.82 116.32 24.71 2.87 
6 74.15±1.64 148.30 31.61 3.44 
7 88.21±1.20 176.42 38.69 3.93 
8 99.25±0.77 198.50 45.59 4.34 
*All values are expressed as mean ±SD, n=3. 
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Table 8.12: In-vitro release drug profile of formulation F2 
    
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 07.19±0.74 14.37 3.54 0.50 
2 14.64±1.06 29.28 7.21 1.02 
3 25.25±0.33 50.50 11.36 1.62 
4 40.07±1.07 80.13 16.54 2.33 
5 55.89±0.69 111.78 22.68 2.93 
6 71.04±1.29 142.09 29.39 3.52 
7 85.06±2.12 170.13 36.36 4.02 
8 96.61±0.98 193.21 43.16 4.41 
 
*All values are expressed as mean ±SD, n=3. 
 
 
Table 8.13: In-vitro release drug profile of formulation F3  
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 06.21±0.61 12.41 3.09 0.50 
2 12.19±0.90 24.38 6.38 1.03 
3 24.12±0.38 48.23 10.34 1.67 
4 39.44±0.63 78.87 15.55 2.40 
5 53.63±0.44 107.25 21.67 2.97 
6 70.67±1.42 141.33 28.37 3.58 
7 82.80±0.88 165.60 35.25 4.01 
8 92.41±0.57 184.82 41.74 4.36 
*All values are expressed as mean ±SD, n=3. 
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Figure 8.14: In-vitro Drug Release profile curve of formulations F1 to F3 
 
Table 8.14: In-vitro release drug profile of formulation F4 
 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 09.25±1.51 18.49 4.61 0.50 
2 16.11±1.06 32.22 8.66 0.93 
3 25.84±0.38 51.67 12.71 1.50 
4 41.03±0.44 82.06 17.81 2.25 
5 54.63±0.38 109.27 23.75 2.81 
6 70.04±0.57 140.07 30.21 3.44 
7 86.41±0.51 172.81 37.15 4.00 
8 96.82±0.57 193.63 44.01 4.38 
 
*All values are expressed as mean ±SD, n=3. 
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Table 8.15: In-vitro release drug profile of formulation F5   
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 07.48±1.03 14.96 3.49 0.50 
2 14.15±1.19 28.30 7.04 1.01 
3 23.61±0.25 47.22 10.92 1.59 
4 39.44±0.72 78.87 15.98 2.37 
5 52.79±0.38 105.57 21.97 2.91 
6 69.83±0.58 139.66 28.53 3.55 
7 84.64±0.32 169.29 35.52 4.07 
8 92.28±0.82 184.57 42.18 4.36 
*All values are expressed as mean ±SD, n=3.      
 
Table 8.16: In-vitro release drug profile of formulation F6 
 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 06.11±0.88 12.21 3.04 0.50 
2 13.07±1.19 26.14 6.30 1.03 
3 22.77±0.63 45.54 10.09 1.64 
4 38.89±0.44 77.78 15.17 2.43 
5 47.33±0.51 94.65 20.72 2.80 
6 66.05±0.50 132.10 26.70 3.58 
7 81.24±0.63 162.49 33.43 4.13 
8 89.05±0.51 178.10 39.94 4.43 
 
*All values are expressed as mean ±SD, n=3. 
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Figure 8.15: In-vitro Drug Release profile curve of formulations F4 to F6 
 
Table 8.17: In-vitro release drug profile of formulation F7 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 08.17±0.88 16.33 4.05 0.50 
2 15.03±0.90 30.07 7.82 0.96 
3 24.29±0.38 48.57 11.80 1.55 
4 37.76±0.63 75.51 16.58 2.23 
5 49.47±0.51 98.94 21.94 2.78 
6 62.65±0.83 125.30 27.62 3.36 
7 78.77±0.45 157.54 33.79 4.01 
8 91.49±0.50 182.97 40.24 4.49 
 
*All values are expressed as mean ±SD, n=3. 
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Table 8.18: In-vitro release drug profile of formulation F8 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 06.50±0.90 13.00 3.24 0.50 
2 13.37±1.03 26.73 6.58 1.02 
3 21.60±0.83 43.19 10.24 1.59 
4 31.38±0.76 62.75 14.28 2.16 
5 46.74±0.32 93.48 19.18 2.94 
6 58.45±0.84 116.90 24.73 3.46 
7 75.03±0.57 150.06 30.74 4.14 
8 87.67±0.44 175.33 37.10 4.63 
 
*All values are expressed as mean ±SD, n=3. 
 
Table 8.19: In-vitro release drug profile of formulation F9 
Time (hours) 
Percentage 
drug released*
 
Amount (mg) % DE MDT 
0 0.00±0.00 0.00 0.00 0.00 
1 05.33±0.74 10.64 2.63 0.50 
2 12.29±1.18 24.57 5.72 1.07 
3 19.79±1.27 39.58 9.20 1.62 
4 28.40±0.58 56.79 12.90 2.16 
5 35.58±0.38 71.15 16.65 2.64 
6 47.25±0.69 94.49 20.73 3.36 
7 61.43±0.51 122.87 25.52 4.09 
8 78.31±0.38 156.61 31.08 4.84 
 
 
*All values are expressed as mean ±SD, n=3. 
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Figure 8.16:  In-vitro Drug Release profile curve of formulations F7 to F9 
 
 
 
 
Figure 8.17: In-vitro Drug Release profile curve for different polymers at 
20%concentration of formulations F1, F4 and F7. 
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Figure 8.18: In-vitro Drug Release profile curve for different polymers at 
                     30% concentration of formulations F2, F5 and F8. 
 
 
 
Figure 8.19: In-vitro Drug Release profile curve for different polymers at  
  40% concentration of formulations F3, F6 and F9. 
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Figure 8.20: Comparative study of Cumulative In-vitro % drug release  
                                    curve of formulation  F1 to F9. 
 
Table 8.20: Time of in vitro drug released for aceclofenac t50% values of F1 to F9. 
Formulation code Time of drug released 
(hours) (t50%) 
F1 4.4 
F2 4.6 
F3 4.8 
F4 4.7 
F5 4.8 
F6 5.2 
F7 5.1 
F8 5.3 
F9 6.2 
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Figure 8.21: In vitro drug release for t50% values of F1 to F9. 
 
Aceclofenac is a water insoluble drug; its release from the matrix is largely 
dependent on the polymer swelling, drug diffusion and matrix erosion. The 
concentration of polymer in the sustained   release layer was a key factor in 
controlling the drug release. Various sustained release formulations were formulated 
with HPMC K15M, Carboxy methyl cellulose, Xanthan gum polymer alone; 
polyvinyl pyrrolidone as binder and microcrystalline cellulose was used as diluents. 
In vitro release studies of formulations F1, F2 and F3 prepared by HPMC 
K15M with concentrations of 20%, 30% & 40% respectively. The drug released from 
formulation F1 to F3 were found to be 99.25 ± 0.77, 96.61 ± 0.98, and 92.41 ± 0.57% 
for aceclofenac respectively.  
In vitro release studies of formulations F4, F5 and F6 prepared by Carboxy 
methyl cellulose with concentrations of 20%, 30%& 40% respectively. The drug 
released from formulation F4 to F6 were found to be 96.82 ± 0.57, 92.28 ± 0.82, and 
89.05 ± 0.51% for aceclofenac respectively.  
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In vitro release studies of formulations F7, F8 and F9 prepared by Xanthan 
gum with concentrations of 20%, 30%& 40% respectively. The drug released from 
formulation F7 to F9 were found to be 91.49 ± 0.50, 87.67 ± 0.44, and 78.31 ± 0.38% 
for aceclofenac respectively.  
The release rate of F9 was found to be higher when compared to other 
formulations this is due to increase in the concentration of polymer (Xanthan gum). 
In vitro release studies of formulations F3, F6 and F9 prepared by with 
concentrations of 30% HPMC K15M, Carboxy methyl cellulose and Xanthan gum 
shows sustained release effects.  
The result of t50% was shown in Table 8.20 and Figure 8.21, according to the 
time of drug release values of t50%, the formulation F9 was selected as the best 
formulation. 
The overall release rate of aceclofenac from carboxy methyl cellulose and 
HPMC K15M matrices are significantly higher than that from xanthan gum matrices; 
were shown in Figure 8.20 and which is confirmed by smaller MDT (4.38, 4.36, 4.43 
and 4.34, 4.41, 4.36) respectively for carboxy methyl cellulose and HPMC K15M and 
higher MDT for xanthan gum matrices. These results are indicating that xanthan gum 
has higher drug retarding ability for long duration than carboxy methyl cellulose and 
HPMC K15M. Xanthan gum also showed the least %DE while carboxy methyl 
cellulose and HPMC K15M also showed the greatest %DE among the tablets with 
just one of the retarding polymers. 
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 Based on the in-vitro drug release data, MDT, %DE and t50%, the formulation 
F9 was selected as the optimized formulation. Hence the formulation F9 was selected 
for the further stability study. 
8.3.9. Data Analysis (Curve Fitting Analysis): 
Korsemeyer-Peppas model indicates that the release mechanism is not well 
known or more than one type of release phenomena could be involved. The „n‟ value 
could be used to characterize different release mechanisms as: 
Table 8.21:   Different drug release mechanisms of kinetic model 
 Release exponent (n) Drug Transport Mechanism 
0.5 Fickian diffusion  
0.45< n=0.89 Non- Fickian diffusion 
0.89 Case II transport 
Higher than 0.89 Super case II transport 
       
It ranges between 0.5 to 1, so it was concluded that the drug release occurred 
via non-fickian diffusion, which shows that the release from initially dry, hydrophilic 
glassy polymers that swell when added to water and become rubbery show anomalous 
diffusion as a result of the rearrangement of macro molecular chains. 
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8.3.2.8. Kinetic studies: 
Table 8.22: In-vitro Release Kinetic models for Aceclofenac sustained release Matrix  
 tablets of formulations (F1 to F9) 
 
F. 
Code 
Zero 
order 
First 
order 
Higuchi Korsemeyer- Peppas Best fit 
model 
R
2
 R
2
 R
2
 R
2
 Slope(n) 
F1 0.989 0.623 0.857 0.992 1.268 Peppas 
F2 0.986 0.725 0.846 0.994 1.302     Peppas 
F3 0.984 0.805 0.842 0.991 1.376 Peppas 
F4 0.986 0.719 0.850 0.987 1.186 Peppas 
F5 0.983 0.803 0.843 0.989 1.279 Peppas 
F6 0.981 0.817 0.838 0.994 1.342 Peppas 
F7 0.986 0.778 0.846 0.991 1.197 Peppas 
F8 0.977 0.792 0.825 0.993 1.279 Peppas 
F9 0.967 0.803 0.813 0.995 1.262 Peppas 
 
 
 
 
 
 
 
Figure 8.22: Best fit model (Peppas) of formulation F1 
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Figure 8.23: Best fit model (Peppas) of formulation F2 
 
 
Figure 8.24: Best fit model (Peppas) of formulation F3 
 
 
Figure 8.25:  Best fit model (Peppas) of formulation F4 
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Figure 8.26:  Best fit model (Peppas) of formulation F5 
 
 
Figure 8.27: Best fit model (Peppas) of formulation F6 
 
 
Figure 8.28: Best fit model (Peppas) of formulation F7 
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Figure 8.29: Best fit model (Peppas) of formulation F8 
 
 
Figure 8.30: Best fit model (Peppas) of formulation F9 
To know the kinetics of the best formulations, the release data was treated 
according to different models. Drug release data of tablets was fitted in peppas 
equation  and found release mechanism to be diffusion.  
           The results of dissolution data fitted to various drug release kinetic equations.  
Model was found to be the best fitted in all dissolution profile having higher 
correlation coefficient followed by the Peppas release equation. The kinetic values 
obtained from different formulations are tabulated in table 8.22. Optimized 
formulation F9 shows the Super case II transport Mechanism. 
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8.4. Stability Study: 
After storage the formulation was analyzed for various physical parameters, 
results are showed in Table 8.23. 
Table 8.23: Stability study of best formulation F9. 
Characteristic Initial 1
st
 Month 2
nd
 Month 3
rd
 Month 
Hardness (kg/cm
2
)* 7.85±0.41 7.67±0.29 7.50±0.00 7.33±0.29 
Drug content (%)* 98.90±0.65 98.85±0.76 98.83±1.03 98.69±0.56 
In vitro drug release at 
8
th 
 hour* 
78.31±0.38 78.22±0.26 78.18±0.40 78.14±0.38 
*All the values are expressed as mean± SE, n=3. 
 
 
 
 
 
 
Figure 8.31: Comparisons of Hardness before and after stability period at   
                     accelerated temperature (40
0 
C ± 2
0 
C / 75% RH ± 5%). 
 
 
 
 Aceclofenac sustained Release Tablets    RESULTS AND DISCUSSION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 120 
 
Figure 8.32: Comparisons of drug content before and after stability period at 
        accelerated temperature (40
0 
C ± 2
0 
C / 75% RH ± 5%). 
 
 
 
Figure 8.33: Comparisons of in vitro Cumulative % drug release before and after                    
                          stability period at Accelerated temperature (40
0 
C ± 2
0 
C / 75% RH ± 
5%) 
 After 3 months of stability studies at 40
0 
C ± 2
0 
C / 75% RH ± 5%, the results 
in the table 8.38 given that the optimized formulation F9 had shown satisfactory 
stability. 
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9. SUMMARY AND CONCLUSION 
 
In present investigation an attempt has been made to design and develop 
Aceclofenac sustained release matrix tablets using HPMC K15M, Carboxy 
methylcellulose and Xanthan gum, as release retarding polymers. Aceclofenac is 
widely used as a centrally acting muscle relaxant; therefore have been selected to 
prepare sustained release dosage forms. 
An ideal matrix formulation prepared with different polymers and diluents 
concentrations should release its content in a sustained profile a reasonable length of 
time and preferably with Korsmeyer-peppas kinetic. 
The active pharmaceutical ingredient Aceclofenac was evaluated for its 
physical characteristics, analytical profiles and drug polymer compatibility study. The 
granules were prepared by wet granulation method. The prepared granules were 
evaluated for Angle of repose, Bulk density, Tapped density and Carr‟s index. The 
results obtained were found to be satisfactory and within the specified limits.  
  After compression parameters like Thickness, Hardness, Weight variation, 
Friability, content uniformity and In-Vitro release studies were evaluated. 
Result of the present study demonstrated that hydrophilic polymers could be 
successfully employed for formulating sustained release matrix tablets of 
Aceclofenac. The investigated sustained release matrix tablet was capable of 
maintaining constant plasma concentration upto 8 hours. This can be expected to 
reduced the frequency of administration and decrease the dose dependent side effects. 
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The efficacy and safety of Aceclofenac tablet dosage form are expected to offer 
optimum therapeutic efficacy and improved patient compliance. 
In the present study the effect of types and concentration of polymer were 
studied on    In-Vitro drug release. It shows that increase in concentration of polymer 
results in the sustained drug release for 8 hours. The study has revealed that by 
increasing concentration of polymer, release rate of drug was retarded and results 
confirmed that the release rate from hydrophilic matrix tablets depends on type and 
concentration of polymer. 
        In present studies, matrix formulation containing Xanthan gum 40% is 
probably showing release up to 78% within 8 hrs. 
According to stability study it was found that there was no significant change 
in hardness, drug content and in vitro dissolution of optimized formulation (F9). 
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10.FUTURE PROSPECTS 
In the present work the sustained release matrix tablets of aceclofenac were 
formulated using hydrophilic polymers such as HPMC, Carboxy methylcellulose and 
Xanthan gum by wet granulation method. In this work only physiochemical 
characterization, formulation and in-vitro evaluation matrix tablets of aceclofenac was 
done. Along with in-vitro release study in-vivo release behavior of drug is also 
important. So in future in-vivo release study using different models are required to set 
the in-vitro in-vivo correlation which is necessary for development of successful 
formulation and also long term stability studies are necessary. 
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